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Abstract
TNF is an inflammatory cytokine that plays a critical role in the acute phase response to
infection, and its dysregulation has been implicated in the pathology of several inflam-
matory and autoimmune disorders. TNF gene expression is regulated in a cell type- and
inducer-specific manner that involves chromatin alterations at both the TNF promoter and
distal DNase I hypersensitive (DH) sites within the TNF/LT locus. While the mechanisms
underlying TNF gene activation in monocytes/macrophages and T cells have been stud-
ied intensively, the mechanisms of enhanced, repressed, and restored TNF gene expression
in the context of classical macrophage activation and endotoxin tolerance remain largely
unknown. We set out to understand how TNF gene expression is modulated during these
biological processes by characterizing the chromatin environment of the TNF/LT locus.
In the context of classical macrophage activation, IFN-γ primes both circulating mono-
cytes and tissue-resident macrophages so that, upon microbial recognition, there is an en-
hanced anti-microbial response; importantly, this results in enhanced TNF transcription.
The mechanisms involved in priming are unclear; the IFN-γ-inducible transcription factors
IRF1 and STAT1 have been implicated, but functional roles for these factors have not been
determined. Here, we show in primary human monocyte-derived macrophages (MDMs)
that IFN-γ poises the TNF/LT locus for enhanced TNF transcription by exposing the distal
enhancer element hHS-8, and that the ability of this element to promote TNF gene expres-
sion in response to priming depends on its recruitment of IRF1. We also demonstrate that
IFN-γ poises hHS-8 for enhancer function by promoting H3K27me3 enrichment, and that
subsequent LPS stimulation triggers hHS-8 enhancer activation through demethylation of
H3K27me3 followed by acetylation of H3K27. These experiments provide a mechanistic
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explanation of how IFN-γ poises the TNF/LT locus for enhanced TNF transcription upon
LPS stimulation, while at the same time providing potential targets for selective manipula-
tion of TNF expression in primed macrophages.
In the context of endotoxin tolerance, repeated or prolonged exposure to LPS results
in the reprogramming of monocytes and macrophages such that inflammatory responses,
especially induction of TNF, are down-regulated; in this regard, the cell is considered toler-
ant or immunosuppressed. Notably, IFN-γ priming has been shown to abrogate endotoxin
tolerance, thereby restoring responses to LPS stimulation. The mechanism of TNF gene re-
pression during endotoxin tolerance and its restoration during IFN-γ-mediated abrogation
remains unknown. Here, we have characterized the TNF/LT locus in endotoxin-tolerant
monocytes and macrophages and found the TNF promoter to be nuclease accessible and
enriched for H3K27me3 during repressed transcription. We have also found that IFN-γ
priming restores TNF gene expression in an IRF1-independent manner, suggesting that
IFN-γ primes non-tolerant and endotoxin-tolerant monocytes and macrophages by two dis-
tinct mechanisms; furthermore, we observed enrichment of H3K27ac at the TNF promoter
and the appearance of a DH site 4kb upstream of the TNF TSS in response to IFN-γ treat-
ment of endotoxin-tolerant cells. These results suggest that chromatin modifications at the
TNF promoter and distal DNA elements play an important role in IFN-γ-mediated abroga-
tion of endotoxin tolerance.
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Chapter 1
Introduction
1.1 Tumor Necrosis Factor (TNF)
The effects of TNF have been documented since the early 1890s when patients with ma-
lignant tumors were observed to undergo spontaneous tumor regression following acute
bacterial infections [1]. In 1962, it was suggested that bacterial lipopolysaccharide (LPS)-
induced tumor necrosis requires additional factors, as evidenced by the fact that LPS treat-
ment did not kill tumor cells in vitro [2]. Finally, in 1975, Carswell and co-workers from
Lloyd Old’s group formally identified TNF in the serum ofMycobacterium (M.) bovis strain
Bacillus Calmette-Guérin (BCG)-immunized mice treated with LPS [3]. They demon-
strated that TNF-positive serum inhibited the growth of two tumor cell lines: Meth A
sarcoma and L929. These results were later confirmed when recombinant TNF (rTNF)
was shown to induce hemorrhagic necrosis of transplanted Meth A sarcomas in mice [4].
Soon after, rTNF was administered to tumor-bearing patients, but side effects were severe
and reminiscent of symptoms associated with sepsis; patients were reported to experience
headache, nausea, vomiting, fever, rigors, anorexia, and diarrhea—all signs of systemic
bacterial infection [5]. These findings marked the beginning of a new stage in TNF re-
search, with focus on TNF as primarily a mediator of host defense and inflammation.
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1.1.1 TNF in infectious disease
TNF, in the context of infectious disease, elicits an array of cellular responses to bacterial,
parasitic, and viral pathogens. It is a potent activator of endothelial cells, which line the
surfaces of the skin, respiratory tract, gastrointestinal tract, oral cavity, genitourinary tract,
and eye. During infection, TNF triggers endothelial cells to secrete soluble (e.g., IL-8,
MCP-1, IP-10) [6–8] and cell surface molecules (e.g., ICAM-1, VCAM-1) [9, 10] that
promote the accumulation of leukocytes and inflammatory mediators to sites of infection.
By increasing local blood flow and vascular permeability, TNF consequently induces the
four cardinal signs of inflammation: heat, pain, redness, and swelling [11]. In addition to
its local effects, TNF is an endogenous pyrogen that induces fever via its effects on the
hypothalamus [12]. Notably, TNF induces the expression of IL-1, which is a significantly
more potent pyrogen than TNF [12, 13].
The creation of mice deficient for TNF signaling led to further insights into TNF biology.
For example, studies using mice with a disruption in the TNF gene (Tnf -/-) have demon-
strated a critical role for TNF in granuloma formation during M. tuberculosis infection.
Granulomas are organized structures consisting of macrophages, epithelioid cells, foam
cells, and multinucleated giant cells that are surrounded by a rim of lymphocytes; the gran-
uloma’s primary function is to contain the bacteria, thereby preventing their dissemination
[14]. In Tnf -/- mice, T cells were found to migrate to the lung but failed to localize in in-
fected alveoli and participate in granuloma formation. In addition, Tnf -/- mice succumbed
to a low dose of aerosolized M. tuberculosis that did not cause mortality in wild-type mice
[15].
Additional studies have demonstrated that mice deficient in the TNF receptor (Tnfr1-/-)
were severely impaired in clearing the intracellular bacteria Listeria (L.) monocytogenes and
Salmonella typhimurium, and readily succumbed to infection [16, 17]. TNF signaling is also
critical for control of non-bacterial pathogens such as the intracellular parasite Leishmania
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(L.) major; Tnfr1-/- mice inoculated with L. major were able to clear infection but failed
to resolve lesions, suggesting a key role for TNF in healing lesions [18]. Finally, herpes
simplex virus-1 (HSV-1) infection was lethal in Tnfr1-/- mice, and, compared to wild-type
animals, Tnfr1-/- mice had significantly higher viral loads in the brain, suggesting a role
for TNF signaling in controlling HSV-1 replication in the central nervous system [19]. In
conclusion, multiple studies using mice deficient in TNF signaling have demonstrated the
importance of TNF in host responses to bacterial, parasitic, and viral infections.
1.1.2 TNF dysregulation and its clinical implications
When over-expressed, TNF is a major mediator of the pathogenesis associated with several
inflammatory and autoimmune disorders; these include rheumatoid arthritis (RA), inflam-
matory bowel disease (IBD), multiple sclerosis, plaque psoriasis, ankylosing spondylitis,
and sepsis [20]. Although the pathogenic cause of most chronic inflammatory diseases is
unknown, the classic inflammatory responses promoted by TNF are thought to account for
chronic inflammatory pathology and tissue damage. For example, RA is characterized by
lymphocyte activation in the peripheral blood, synovium, and synovial fluid; this causes in-
flammation in the joints and surrounding tissues. Examination of synovial fluid from symp-
tomatic joints of RA patients showed the presence of active TNF [21], and stimulation of
synovial fibroblasts with TNF resulted in the production of collagenase and prostaglandin
E2, which are known to mediate bone resorption by osteoclasts [22]. In addition, chronic
over-production of TNF in mutant mice lacking the TNF AU-rich elements (TNFΔARE) cor-
responds with inflammatory arthritis. AU-rich elements are sequences that help regulate
TNF mRNA degradation and translational repression in hematopoietic and stromal cells
[23]. Joints of TNFΔARE mice exhibited features of chronic symmetrical inflammatory pol-
yarthritis; indeed, both early and later stages of disease displayed characteristics comparable
to human rheumatoid arthritis [24].
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Anti-TNF therapy has been in clinical use since 1998 and has been overwhelmingly suc-
cessful for the treatment of inflammatory diseases, particularly RA and a type of IBD known
as Crohn’s disease (CD). Two anti-TNF antibodies (infliximab and adalimumab) [25, 26]
and a soluble TNF receptor fusion protein (etanercept) [27] bind and neutralize both solu-
ble and membrane-bound TNF. These three biologics fuel a major part of the $20+ billion
global market for TNF inhibitors and have been used to treat more than 2 million patients
worldwide. Two novel TNF inhibitors, certolizumab pegol [28] and golimumab [29] have
recently entered the market and have been approved for the treatment of CD and RA, re-
spectively [30].
CD is the other major inflammatory disorder treated with TNF inhibitors; it is a type of
IBD, along with ulcerative colitis [31]. CD is a chronic gastrointestinal disorder character-
ized by persistent disturbances between the commensal bacteria of the normal microbiome
and the gut lumen, resulting in the induction of mucosal inflammation. TNFwas first linked
to the inflammatory responses of CD when higher levels of TNF were found in the mucosa
and stools of CD patients as compared to those of healthy individuals [32]. In addition,
TNF-positive macrophages were significantly increased in the lamina propria of CD in-
testinal specimens than that of control specimens [33]. These and other studies led to the
1998 US FDA approval of infliximab as the fist monoclonal antibody for CD treatment
[34].
Although anti-TNF therapy has been extraordinarily successful in the last two decades,
there are certainly adverse effects associated with global ablation of such a critical, non-
redundant cytokine. Patients receiving TNF inhibitors have an increased risk for intracellu-
lar bacterial infections, including Mycobacteria [35], Listeria, Salmonella, and Legionella
[36]. In fact, patients are required to undergo latent tuberculosis (TB) screening before
initiating anti-TNF therapy; this is done as an effort to reduce the risk of TB reactivation
[37].
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In an effort to address the complications following systematic and continual TNF in-
hibition, recent studies have investigated the effects of selectively inhibiting TNF secreted
from specific cell types [38]. The motivation is to primarily inhibit “pathogenic TNF” while
sparing TNF that is essential for effective host defense. One study using mice deficient for
TNF expression only in myeloid cells (i.e., monocytes, macrophages, neutrophils) showed
that TNF produced by myeloid cells has a critical, non-redundant role in the early stages of
M. tuberculosis infection but becomes redundant in the later stages of infection [39]. These
mice were able to control chronic infection by recruiting activated, TNF-producing CD4+
and CD8+ T cells. In contrast, mice deficient for TNF expression only in CD4+ and CD8+
T cells were able to contain early M. tuberculosis infection but not persistent infection.
Although granulomas were established, mice deficient for TNF in T cells were unable to
efficiently recruit effector T cells to granulomas, thereby impairing the structural and func-
tional integrity of granulomas during chronic infection. The authors conclude that TNF
expressed from myeloid cells is primarily responsible for early immune function and that
TNF expressed from T cells is essential to sustain protection against chronic TB infection.
Thus, inhibition of TNF derived from T cells during latent M. tuberculosis infection may
promote TB reactivation, suggesting that novel therapies for autoimmune diseases that are
directed against myeloid-derived TNF would be preferable in latently infected TB patients.
In addition to directly suppressing TNF that is secreted from specific cellular sources,
intracellular signaling mechanisms responsible for TNF production are also attractive tar-
gets for efforts aimed at developing more specific and less toxic anti-TNF therapies. In this
regard, it is important to understand the mechanisms involved in regulation of TNF expres-
sion in various cell types at the level of both signal transduction pathways and chromatin,
which was the overarching goal of this work.
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1.2 Role of IFN-γ in macrophage function
Aseries of studies in the 1960s that examinedL.monocytogenes infection in BCG-immunized
mice introduced the theory that macrophage activation requires a humoral factor released
by lymphocytes in the presence of a specific antigen [40]. This unknown factor was later
named IFN-γ [41]. In the 1980s, it was established that IFN-γ and macrophage-activating
factor (MAF) are one and the same when IFN-γ was shown to prime murine peritoneal
macrophages for enhanced antiviral activity and LPS-induced tumor cell killing [42–44].
Since then, IFN-γ priming has been shown to enhance various monocyte and macrophage
functions, including pathogen recognition, antigen presentation, microbial killing, receptor-
mediated phagocytosis, and promotion of CD4+ T cell differentiation toward a Th1 pheno-
type [45].
1.2.1 IFN-γ priming
Classical macrophage activation
Natural Killer (NK) cells, Th1 lymphocytes, and CD8+ cytotoxic lymphocytes were orig-
inally thought to be the exclusive sources of IFN-γ; however, subsequent studies have
demonstrated IFN-γ secretion from other cell types, including B cells, NKT cells, and
antigen-presenting cells (APCs) [46–50]. In the early stages of bacterial infection, macrophages
secrete chemokines and cytokines (i.e., IL-12 and IL-18) that both attract NK cells to the
site of inflammation and induce their production of IFN-γ [51]. In addition, IL-12 and IL-18
drive Th1 differentiation of antigen-specific naïve T cells, which also go on to secrete IFN-γ
[52]. IFN-γ subsequently converts resting macrophages into potent microbial killers, a pro-
cess known as classical macrophage activation. Many TLR agonists, like LPS, are known
to effectively activate macrophages without the assistance of IFN-γ [53], but the action of
IFN-γ priming is essential for robust innate immunity characterized by potent macrophage
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activity. Most notably, IFN-γ primes monocyte and macrophage responses to TLR ago-
nists, thereby augmenting the transcriptional expression of critical inflammatory mediators
such as TNF [54], IL-12 [55, 56], IL-6 [57], and NO [58]. In one study, relatively increased
TNFmRNA levels were detected in LPS-stimulated primary humanmonocytes primedwith
IFN-γ as compared to unprimed cells [59]. The authors also showed that pretreatment of
monocytes with IFN-γ for 2h was sufficient for augmented TNF mRNA levels, and that the
effects of IFN-γ lasted for up to 40h after treatment. Similar findings were reported for IL-
12 p35 mRNA levels in human PBMCs [60], IL-6 mRNA levels in the human monocytic
cell line THP-1 [57], and NO mRNA levels in a mouse macrophage cell line [58]. A major
goal of this work was to determine the mechanism responsible for IFN-γ priming, which,
until now, has been unclear.
The importance of IFN-γ for innate immunity is evidenced by the clinical outcomes of
patients lacking IFN-γ, its receptor, or its key signaling molecules. It has been observed in
clinical studies that patients with disrupted IFN-γ signaling show increased susceptibility
to mycobacterial infection; in particular, a deletion of nucleotide 131 in the gene for IFN-γ
receptor 1 (IFNGR1) that results in a frame-shift and loss of IFNGR1 surface expression
was found in a child with fatal idiopathic disseminated BCG infection [61]. In a similar
study, a mutation (395A>C) in IFNGR1 was associated with severe mycobacterial infec-
tions in four Maltese children [62]. This mutation led to decreased surface expression of
IFNGR1 in PBMCs. The authors speculated that increased susceptibility to mycobacterial
infection in the affected patients was primarily due to macrophage impairment, particularly
impaired macrophage activation. Notably, PBMCs from the affected patients were stimu-
lated with IFN-γ and LPS, and IFN-γ was unable to enhance TNF levels in patient PBMCs,
as compared to control cells. Other children with disseminated atypical mycobacterial in-
fection, who also had impaired IFN-γ production, exhibited defective TNF production in
response to IFN-γ and LPS [63]. In conclusion, understanding the mechanisms responsible
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for IFN-γ-induced macrophage activation has clinical implications for host defense against
mycobacteria and a number of other intracellular organisms.
Endotoxin tolerance and its abrogation
Formally, endotoxin tolerance is the phenomenon inwhich immune cells, primarilymono-
cytes and macrophages, transiently become hyporesponsive or “tolerant” upon repeated or
prolonged exposure of LPS [64]. Physiologically, endotoxin tolerance is considered to be a
negative feedback response that protects the host against uncontrolled inflammation, as seen
in sepsis and severe tissue injury. One of the earliest documentations of endotoxin toler-
ance reported reduced fever responses in rabbits undergoing daily injections of typhoid vac-
cine [65–67]. This phenomenon of endotoxin tolerance was characterized as transient, evi-
denced by the finding that 3 weeks without injections rendered the rabbits responsive again.
Decades later, induction of endotoxin tolerance in mice was shown to be a macrophage-
mediated response [68]. Specifically, when LPS-resistant mice (later found to be defective
for the LPS signaling receptor) were given LPS-sensitive macrophages from a wild-type
mouse, they became susceptible to lethal challenges of LPS. In addition, when a group of
these transplanted mice were first challenged with non-lethal doses of LPS and then sub-
jected to a lethal dose of LPS, all mice survived, thereby demonstrating that macrophages
are the primary mediators of endotoxin tolerance. Subsequent in vitro studies have shown
induction of endotoxin tolerance in human monocytes and macrophages with reduced TNF
expression as the primary readout [69–71].
Though endotoxin-tolerant monocytes and macrophages are often characterized as un-
or hyporesponsive, these cells do adopt “active” mechanisms of control as well. In partic-
ular, gene expression of anti-inflammatory cytokines like IL-10, TGF-β, and IL-1RA was
shown to be enhanced in monocytes from sepsis patients, as compared to those from healthy
donors [72]. Another study observed increased internalization of Escherichia coli cells in
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endotoxin-tolerant monocytes as compared to non-tolerant monocytes; additionally, higher
levels of the surface receptor CD64, a well-known marker for phagocytosis, were found on
endotoxin-tolerant monocytes as compared to non-tolerant monocytes [71]. Together, these
results discredit the picture of endotoxin tolerance as macrophage “immunoparalysis”.
Notably, IFN-γ has been shown to prevent the induction of endotoxin tolerance in human
monocytes and macrophages. Co-treatment with recombinant IFN-γ during an initial chal-
lenge of LPS was shown to prevent endotoxin tolerance in Mono-Mac-6 cells, as evidenced
by a restored induction of TNF mRNA levels upon a second challenge of LPS; notably, this
was not observed in response to IFN-α and IFN-β priming [73]. Whether IFN-γ priming
has a similar effect in both resting and endotoxin-tolerant monocytes is unknown. Indeed,
the mechanisms responsible for endotoxin tolerance and IFN-γ-mediated abrogation remain
unclear, and a major goal of the work described herein was to elucidate molecular mecha-
nisms involved in these processes.
1.2.2 Crosstalk between IFN-γ and LPS signaling pathways
Components of the IFN-γ and LPS signaling pathways interact in various ways to enhance
macrophage responses, as seen in resting monocytes and macrophages primed by IFN-γ
[74]. The individual IFN-γ and LPS signaling pathways, and the interplay between compo-
nents of the two signaling pathways, are described below.
IFN-γ signaling pathway
Signal transducer and activator of transcription-1 (STAT1) is the primary mediator of
IFN-γ signaling [75]. IFN-γ binds to the IFN-γ receptor (IFNGR1), leading to the trans-
phosphorylation and activation of receptor-associated janus kinase (JAK) 1 and JAK2 [76]
(Figure 1.2.1). JAK1 then phosphorylates a subunit of IFNGR1 at tyrosine residue 440
(Y440) [78], thereby creating a docking site for STAT1. Via its SH2 domain, STAT1 binds
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Figure 1.2.1: The IFN-γ signaling pathway. IFN-γ signaling activates the classical JAK/STAT pathway leading
to STAT1 homodimerization and nuclear translocation. STAT1 binds to gamma-activated sequence (GAS) and
activates the transcription of several primary response genes, including IRF1. Courtesy of (Saha, 2010) [77]
to the receptor and is then activated by phosphorylation of its tyrosine residue 701 (Y701)
[79, 80]. Phosphorylated STAT1 homodimerizes, translocates to the nucleus, binds to a
DNA element called gamma-activated sequence (GAS), and activates transcription of sev-
eral primary response genes [77]. Notably, Stat1-/- and Ifng-/- mice have similar pheno-
types in that they are non-responsive to both IFN-α and IFN-γ and are highly susceptible to
microbial infection [75, 81].
One major primary response gene that is activated by IFN-γ signaling encodes Interferon
Regulatory Factor 1 (IRF1). The IRF family consists of nine transcription factors that play
pivotal roles in IFN-mediated immune responses [82]. IRF1 mediates the activation of
several IFN-γ-inducible genes, including NOS2, CASP1, COX2, and CIITA. Interestingly,
Irf1-/- mice exhibit impaired production of IL-12, which is an inducer of IFN-γ in T lym-
phocytes and NK cells [83]. Indeed, IRF1 recruitment to the IL12A promoter was shown
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Figure 1.2.2: The TLR4/LPS signaling pathway. LPS signals through the TLR4 receptor and activates a MyD88-
dependent or MyD88-independent pathway. The MyD88-dependent pathway involves NF-κB activation while the
MyD88-independent pathway involves IRF3 activation and IFN-β expression. Courtesy of (Akira, 2004) [90]
to be necessary for enhanced IL-12 expression in monocytes primed by IFN-γ [84]. Thus,
IFN-γ induces a positive feedback loop that is mediated by IRF1.
TLR4/LPS signaling pathway
With the help of several molecules, LPS binds to the extracellular domain of TLR4 and
induces a signal transduction cascade that ultimately promotes (and suppresses) the expres-
sion of hundreds of genes [85]. Efficient recognition of LPS by TLR4 requires the co-
receptor CD14 [86], LPS-binding protein (LBP) [87], and the accessory molecule MD-2
[88]. Signaling events downstream of TLR4 occur in either a MyD88-dependent or inde-
pendent manner [89] (Figure 1.2.2). Importantly, production of TNF, IL-1β, and IL-6 in
response to LPS was completely abolished in MyD88-deficient mice, highlighting the im-
portance of this adaptor protein for expression of a subset of inflammatory genes [91]. Once
MyD88 associates with TLR4, it recruits members of the IRAK family such as IRAK1,
IRAK2, and IRAK4 [92]. IRAK4 phosphorylates IRAK1 [93], leading to their dissociation
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from the receptor. IRAK1 binds TRAF6 [94] inducing the formation of a membrane-bound
complex comprising IRAK1, TRAF6, TAK1, TAB1, and TAB2. TAK1 then activates IκB
kinases (IKKs), which then form a complex, phosphorylate, and degrade IκB, an inhibitor
of the transcription factor NF-κB. This results in the activation and nuclear translocation
of NF-κB [95]. There are five subunits of the NF-κB family, but the subunits p50 and p65
associate to form the canonical NF-κB heterodimer, in which p50 binds to cognate DNA
sequences and p65 activates transcription [96]. In addition to NF-κB, other important tran-
scription factors like AP-1 and IRF5 are activated in a MyD88-dependent fashion [97].
Interestingly, there is a subset of LPS-inducible genes whose expression is not impaired in
MyD88-deficient macrophages; these genes are induced via a MyD88-independent mech-
anism that requires IFN-β [98]. Upon LPS binding, TRAM is recruited to TLR4, resulting
in the recruitment of TRIF [99, 100]. Subsequent events involving either RIP1 or TRAF6
lead to activation of NF-κB and AP-1 while events involving TBK1 lead to IRF3 activa-
tion by phosphorylation [90]. IRF3 and NF-κB assemble at the IFNB enhancer with other
transcription factors and coactivators, thereby mediating the induction of IFNB gene ex-
pression. IFN-β, in turn, activates STAT1, which, as outlined above, leads to the induction
of various inflammatory genes.
IFN-γ regulates TLR4/LPS signaling components
IFN-γ upregulates the expression of several TLR4/LPS signaling components. In hu-
man monocytes and macrophages, IFN-γ treatment was shown to augment TLR4 mRNA
and TLR4 surface expression, as well as expression of crucial components of the receptor
complex (i.e., MD-2 and MyD88) [101, 102]. In addition, LPS-induced phosphorylation of
the downstream adaptor protein IRAK1 was significantly increased in endotoxin-tolerant
monocytes treated with IFN-γ as compared to cells that were not treated with IFN-γ [103].
One study showed that treatment of monocytes with IFN-γ promoted IκB degradation and,
12
in turn, enhanced the DNA binding activity of NF-κB via EMSA analysis [104]; however,
in another study, it was reported that IFN-γ does not affect IκB degradation but instead in-
creases the expression of the NF-κB subunit p65 [105]. In any case, these combined data
indicate that IFN-γ sensitizes the macrophage to LPS by upregulating crucial components
for the receptor complex and by enhancing the activity of downstream signaling compo-
nents.
In addition to enhancing TLR4/LPS signaling, IFN-γ suppresses feedback inhibitory
mechanisms induced by TLR4/LPS signaling. IL-10 is a major anti-inflammatory cytokine
that inhibits the activity of monocytes and macrophages, particularly the LPS-induced pro-
duction of inflammatory cytokines [106]. IFN-γ has been shown to repress IL-10 produc-
tion by inhibiting the transcription factor CREB, a critical component for IL10 transcription
[107]. Specifically, IFN-γ promotes phosphorylation and subsequent activation of glycogen
synthase kinase 3β (GSK3β), a kinase that inhibits the function of AP-1 and CREB. The
mechanism responsible for IFN-γ-mediated phosphorylation of GSK3β remains unclear.
Another mechanism by which IFN-γ inhibits anti-inflammatory responses to LPS stimu-
lation involves the disruption of TGF-β signaling. Smad3 is an essential mediator of TGF-β
signaling and induction of TGF-β-inducible genes. IFN-γ has been shown to impair Smad3
activation by (i) inhibiting its phosphorylation and subsequent nuclear translocation and
(ii) inducing Smad7, an antagonistic Smad that prevents Smad3 interaction with the TGF-β
receptor [108]. In conclusion, IFN-γ enhances innate immune activation by LPS via mech-
anisms that both promote inflammatory signaling processes and inhibit anti-inflammatory
responses [109].
LPS regulates IFN-γ signaling components
As outlined above, IFN-γ augments LPS-induced signaling and the inflammatory re-
sponse. At the same time, LPS has been shown to enhance the effects of IFN-γ stimulation
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by increasing STAT1 phosphorylation at serine 727 (S727). Specifically, LPS stimulation in
murine macropahges was shown to dramatically increase STAT1 phosphorylation at S727
at levels comparable to macrophages stimulated with IFN-γ [110, 111]. Again, STAT1 goes
on to bind GAS and activate transcription of numerous IFN-γ-inducible genes. In addition
to STAT1, LPS also activates the transcription factor PU.1 by phosphorylating its serine
residue 148 (S148). PU.1 is a member of the Ets family of transcription factors and plays a
pivotal role in macrophage maturation. Notably, PU.1 associates with IRF8, thereby form-
ing a complex that binds GAS and enhances the expression of some IFN-γ-inducible genes
[112].
1.3 Role of chromatin in inflammatory gene regulation
Identifying and characterizing signal transduction pathways is undoubtedly an essential pro-
cess for defining regulatory mechanisms of the inflammatory response; however, recent
studies have argued that chromatin status must be considered when explaining the selective
nature of these mechanisms. In most instances, pathogen recognition by innate immune
components results in the simultaneous transcriptional induction and inhibition of hundreds
of genes whose chromatin environments are unique at each individual locus. Thus, it is crit-
ical to understand the many factors that comprise chromatin and regulate its conformational
status in order to fully define themechanisms responsible for inflammatory gene expression.
When characterizing chromatin, several factors must be considered. These include DNA
accessibility, transcription factor occupancy, histone modifications, DNA methylation, and
higher-order organization.
1.3.1 Chromatin accessibility
In eukaryotes, DNA is packaged into chromatin, whose basic repeating unit is the nucleo-
some [113, 114]. Each nucleosome consists of 146bp of DNAwrapped around an octamer
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of four core histones [115]. When packaged into chromatin, DNA is relatively inaccessible
to the TATA-binding protein and other factors that help mediate transcription; thus, nucle-
osomal DNA is considered to be repressive to gene expression. Importantly, regions of
accessibility are created by the loss or remodeling of nucleosomes, which, in turn, pro-
vide docking sites for transcription factors and coregulators that bind DNA. Consequently,
chromatin accessibility marks regions of DNA that function as regulatory elements such as
promoters, enhancers, silencers, insulators, and locus control regions [116].
To detect regions of DNA accessibility in chromatin, investigators have traditionally re-
lied on methods derived from the early finding that genomic regions that are accessible to
transcription factors have a pronounced sensitivity to nuclease digestion, especially DNase
I digestion [117, 118]. In fact, these regions are typically two orders of magnitude more sen-
sitive to DNase I than nucleosomal DNA [116]. Pairing DNase I digestion with assays like
Southern blotting, quantitative-PCR (qPCR), or DNA sequencing allows for the identifica-
tion of regions that are accessible or hypersensitive to DNase I. These regions are termed
DNase I hypersensitive (DH) sites and are usually markers of regulatory DNA elements
[119, 120].
Within a given cell type, DH sites can either be constitutive or inducible [116]. Constitu-
tive DH sites, as their name suggests, are independent of gene expression. Generally, these
sites comprise promoter regions and are considered to be poised for transcriptional induc-
tion. In contrast, inducible DH sites appear prior to transcription and may persist long after
the inducing agent is removed. One of the first inducible DH sites to be identified is in the
IL2 locus, which encodes IL-2, a pleiotropic cytokine produced by activated T cells [121];
human peripheral blood T cells were stimulated with mitogen, and an additional DH site
appeared within the IL2 promoter region. Since then, inducible DH sites have been found
to not only be associated with transcriptional activation but also with transcriptional repres-
sion, demonstrating the diverse regulatory functions that individual DH sites can serve.
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Recent studies have attempted to identify all DH sites in a given tissue or cell typewith the
aim of understanding cell type- or disease-specific regulatory networks. The Encyclopedia
of DNA Elements (ENCODE) project has identified 2.9 million unique, non-overlapping
DH sites within the human genome [122]. A small proportion (5%) of these sites local-
ize to regions within 2.5kb of a transcriptional start site (TSS), while the majority of sites
localize to regions greater than 2.5kb but within 250kb of a TSS. When classifying sites
into either promoter or distal DH sites, the ENCODE authors designated any site found to
be within 1kb upstream of a TSS as a promoter DH site. In addition, 34% of these sites
were specific to a single cell type while 14% were detected in all 29 cell types examined.
Interestingly, promoter DH sites generally were accessible across cell types in contrast to
distal DH sites, which were found to be more limited to specific cell types. The differences
in the degree of cell type specificity between promoter and distal DH sites highlight the im-
portance of distal regulatory elements in the control of cell type-specific gene expression.
Notably, a vast majority of the distal DH sites exhibited chromatin features specific to
enhancers. By definition, an enhancer is a small segment of DNA that augments transcrip-
tion driven by its target promoter, which can be anywhere from several to hundreds of
kilobases away [123]. For example, the limb bud enhancer for the mouse Sonic hedgehog
(Shh) gene is located more than 1Mb from the Shh promoter [124]. Given the extreme vari-
ability among known enhancers in distance, orientation, and position relative to the target
promoter, it is difficult to propose a single mechanism for enhancer function.
A representative example of enhancer complexity is found at the IFNB locus. Gene ex-
pression of IFN-β, an anti-viral cytokine primarily involved in innate immunity, utilizes a
virus-inducible enhancer that is one of the best-characterized eukaryotic enhancers [125].
Proximal to the IFNB promoter, the enhancer is a 50bp element located 100bp upstream
of the IFNB TSS. The enhancer is subdivided into four positive regulatory domains (PRDs)
designated PRDI, PRDII, PRDIII, and PRDIV; together, in response to appropriate stimula-
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Figure 1.3.1: Structure of the canonical nucleosome. The histone octamer, illustrating the position of the N-
terminal histone tails that are targets of post-translational modifications. Histones H3, H4, H2A, and H2B are shown
in blue, green, yellow, and red, respectively. Diagram of a 2.8Å resolution structure [128, 129]. (Protein Data Bank
code 1AOI) Kindly provided by Karolin Luger.
tion, these elements recruit a combination of factors that cooperatively bind and ultimately
increase chromatin accessibility at the TATA box [126]. The IFNB enhancer provides one
model of how chromatin accessibility is increased by a regulatory element; indeed, there
are a variety of mechanisms that can be used to remodel chromatin.
1.3.2 Chromatin remodeling
Histone modifications
Considering the importance of chromatin accessibility for gene activation, many studies
attempt to answer how chromatin is remodeled. Chromatin remodeling can be defined as
any event that alters nuclease sensitivity of a region of chromatin [127]; one such event is
the covalent modification of histones. There are five major families of histones: H1, H2A,
H2B, H3, and H4. Typically, a nucleosome comprises two H2A/H2B heterodimers and an
H3/H4 tetramer (Figure 1.3.1). Between each nucleosome core lies a stretch of linker DNA
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ranging from 10 to 90bp that is either naked or bound by histone H1. Extending from the
core domains are histone tails, which are often subjected to post-translational modifications
like acetylation, methylation, ubiquitination, and phosphorylation; in fact, over 100 distinct
histone modifications have been described [130].
Reversible histone acetylation was first proposed to be associated with transcriptional
activity in eukaryotic cells in 1964 [131, 132]. This process locally relaxes chromatin
by removing the positive charge on histone tails, thereby decreasing their affinity for the
negatively charged phosphate groups of DNA. Consequently, histone acetylation promotes
access to DNA for transcriptional regulatory factors. Histone acetyltransferases (HATs)
transfer an acetyl group to the lysine residues of N-terminal histone tails, while histone
deacetylases (HDACs) remove the acetyl group[133].
Histone acetylation has an important role in the activation of inflammatory genes. One
such example is the gene CSF2 encoding granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), which is an inducible cytokine that functions to promote a Th1-biased im-
mune response. Increased CSF2 gene expression involves acetylation of lysine 8 and lysine
12 of histone 4 (H4K8ac and H4K12ac, respectively) at the human CSF2 promoter [134].
Importantly, a specific stimulus can induce gene expression at different loci through distinct
patterns of histone acetylation. For example, infection of human endothelial cells with L.
monocytogenes was shown to upregulate both IL8 and IFNG gene expression; however, in-
creased H3ac and H4ac levels were only observed at the IL8 promoter and not at the IFNG
promoter [135].
Unlike acetylation, histone methylation does not chemically alter the charge of histone
tails; rather, the effects of mono-, di-, and trimethylation of lysine and arginine residues
are thought to indirectly affect gene regulation. Methylation of particular lysine residues
is associated with gene activation (H3K4) and repression (H3K9 and H3K27) [136]. In
the case of H3K9, trimethylation appears to enhance nucleosome stability and promote
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heterochromatin formation by increasing the affinity of adapter proteins to the histone tail.
Specifically, Swi6, a yeast ortholog of heterochromatin protein 1, forms a complex with
H3K9me3-modified tails that ultimately facilitates heterochromatin spreading [137]. In the
case of H3K27, trimethylation increases the affinity of the chromodomain of the Drosophila
Polycomb protein for histone tails, which is implicated in the maintenance of gene silencing
[138, 139]. The precise mechanisms of Polycomb-mediated repression remain unknown.
The balance of histonemethylation ismaintained by the interplay between histonemethyl-
transferases and demethylases. EZH2, a subunit of Polycomb repressor complex 2, is a hi-
stone methyltransferase that has been shown to catalyze methylation of H3K27 [140–142].
JumonjiD3 (JMJD3) and UTX, two related histone demethylases specific to H3K27me3
[143–146], were shown to regulate inflammatory responses in the context of macrophage
activation [147]. Inhibiting both JMJD3 and UTX activity in primary human macrophages
resulted in reduced inflammatory cytokine levels upon LPS stimulation. In addition, JMJD3
and UTX inhibition prevented both the LPS-induced loss of H3K27me3 at, and the recruit-
ment of RNA polymerase (Pol) II to, the TNF promoter [147].
Findings from recent studies have helped support the theory of “histone crosstalk” where
different histone modifications “communicate” in elaborate combinations to remodel chro-
matin [148]. Within a population of numerous and distinct histone modifications, the order
of adding and removing neighboring modifications has been shown to affect transcriptional
readouts. For example, in the context of T cell activation, it has been found that H3K4me3
promotes H3K9ac and H4K16ac enrichment [149]. Specifically, when human CD4+ T
cells were treated with HDAC inhibitors, a subset of gene promoters that were enriched for
H3K4me3 also became enriched for H3K9ac and H4K16ac; in contrast, promoters lacking
H3K4me3 did not become enriched for H3K9ac or H4K16ac. Notably, the increase in his-
tone acetylation corresponded to increased Pol II recruitment but not transcription initiation.
Interestingly, a subunit essential for methylation of H3K4 has been shown to associate with
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an acetyltransferase that recognizes H4K16 [150, 151]. These data indicate that H3K4me3
poises a subset of silent genes in resting T cells for histone acetylation, suggesting crosstalk
among these histone modifications.
In addition to the covalent modification of histones, nucleosomes can be modified by
deposition of histone variants in a replication-independent manner [152]. Histone variants
are defined as non-allelic isoforms of canonical histones that differ in DNA sequence and,
in some cases, amino acid sequence [153]. Replacement of canonical histones with his-
tone variants can alter the packaging structure of nucleosomes, often leading to a less stable
nucleosome [154]; indeed, histone variants H2A.Z and H3.3 have been shown to preferen-
tially localize near transcriptionally active genes, particularly at promoters and enhancers
[155–157]. For example, in one study IFN-β stimulation triggered extensive and prolonged
H3.3 deposition at the 3’-coding regions of IFN-inducible genes like Stat1 [158]. Specif-
ically, IFN-β-induced transcription was significantly reduced in mouse embryonic fibrob-
lasts where H3.3 was knocked down by shRNA. This data supports the finding that histone
variants play a major role in chromatin remodeling and transcription.
Chromatin-remodeling enzymes
Chromatin-remodeling enzymes can be defined as transcriptional regulators that promote
transcription factor binding by altering nucleosome packaging [127]. Importantly, they
lack DNA-binding specificity and must be recruited by other mechanisms, these involve
interactions with transcription factors, histone modifications, and non-coding RNAs [159,
160]. Generally, chromatin-remodeling enzymes fall into one of three categories: i) ATP-
dependent remodeling enzymes; ii) histone-modifying enzymes; and iii) DNA-modifying
enzymes [161].
The ATP-dependent SWI/SNF complex was one of the first chromatin-remodeling com-
plexes to be analyzed in the context of inflammatory gene regulation. Upon ionomycin and
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PMA stimulation, SWI/SNF was found to rapidly associate with chromatin, as evidenced
by nuclear localization, in murine lymphocytes [162]. Subsequent studies have examined
the role for SWI/SNF in macrophages activated by LPS and have found that SWI/SNF
discriminates between secondary and primary response genes [163]. Specifically, sec-
ondary response genes and primary response genes with delayed kinetics were found to
be SWI/SNF-dependent while rapidly induced primary response genes were found to be
SWI/SNF-independent. Furthermore, the promoters of SWI/SNF-dependent genes were
found to be relatively inaccessible prior to LPS stimulation as compared to the promot-
ers of SWI/SNF-independent genes, which were nuclease accessible, suggesting a poised
promoter state exists for rapidly induced primary genes.
In addition to activating gene expression, chromatin-remodeling enzymes are known to
repress gene expression by promoting chromatin inaccessibility. For example, nuclear re-
ceptor complex (NCoR) is an essential component of chromatin-remodeling complexes that
repress genes through a combination of HDAC and other enzymatic activities. During
macrophage activation, dissociation of NCoR from a subset of inflammatory genes was
shown to correlate with gene activation, suggesting NCoR and its accompanying complex
function as active repressors of gene activation in resting macrophages [164]. Notably, the
transcription factor c-Jun was found to be required for NCoR association with DNA, and
LPS-induced phosphorylation of c-Jun led to disassociation of both c-Jun and the NCoR
complex at activated genes [164]. Together, these data suggest a mechanism of LPS-
induced gene activation that involves the removal of a repressive chromatin-remodeling
complex.
Pioneer transcription factors
It is poorly understood how transcription factors, chromatin-remodeling enzymes, and
histone variants are initially recruited to sites of repressed and/or inaccessible chromatin.
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One possibility involves pioneer factors, a special class of transcription factors that can
bind to relatively inaccessible DNA prior to the binding of other factors and gene activa-
tion [165]. Notably, the DNA binding domain of the pioneer factor FOXA1 was shown
to resemble that of linker histone [166], which is known to bind nonspecifically to nucle-
osomes [167]. Pioneer factors are thought to either directly initiate chromatin remodeling
events or to mediate the recruitment of chromatin remodeling factors to a particular region
of DNA. A recent study examining the pioneer factor PU.1 in murine macrophages argued
that pioneer factors may mark enhancers that will later become activated by developmental
or environmental cues [168]. The authors looked at global PU.1 and p300 recruitment in
both resting and LPS-treated murine macrophages and found PU.1 recruitment to be similar
in both conditions while p300 recruitment was expectedly enriched at distal DNA elements
upon LPS stimulation. Importantly, approximately half of the sites where inducible p300
recruitment occurred overlapped with sites of constitutive PU.1 binding. Thus, PU.1 ap-
peared to constitutively mark distal DNA elements for LPS-induced p300 binding [168].
1.3.3 Chromatin looping
With the advent of chromosome conformation capture (3C) technology, the functional im-
plications of chromatin looping have been more thoroughly examined. Chromatin looping
has long been proposed as a mechanism underlying the function of eukaryotic enhancers,
allowing for the enhancer to be brought into close proximity with its target promoter while
simultaneously looping out intervening DNA [169]. Although DNA looping has been pow-
erfully demonstrated by electron microscopy, microscopy does not allow for systematic
studies of DNA topology at a high resolution [170]. Thus, 3C and its derivative assays
have allowed for in vivo population-based analyses of nuclear organization at an unprece-
dented resolution.
In 3C-based assays, cells are fixed with formaldehyde, as is done in chromatin im-
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munoprecipitation, to cross-link DNA/DNA, DNA/protein, and protein/protein interactions
[171]. Chromatin is then digested, ligated under dilute conditions, and analyzed by PCR for
chromatin interactions. Importantly, dilute conditions promote ligation of DNA ends that
are in close proximity to one another, which in turn favors the ligation of junctions between
cross-linked DNA fragments. The frequency of interactions is measured by the abundance
of amplified PCR product and is compared to the random frequency with which various
loci interact. Additional 3C-based assays exist that examine the role of a specific protein of
choice or allow for genome-wide investigations of intra- and/or interchromosomal interac-
tions [172].
A major finding using 3C technology is that, over an extent of 120kb, the promoters for
the genes encoding TH2 cytokines (i.e., IL-4, IL-5, and IL-13) are in close spatial proximity
to one another [173]. This configuration was found in both CD4+ T lymphocytes and NK
cells, but was found to be absent in both B cells and fibroblasts. Essentially, a chromatin
hub of interacting elements at the TH2 cytokine locus forms in a cell type-specific manner.
Another major study utilized 3C-based methods with data from the ENCODE consortium to
comprehensively examine long-range interactions between TSSs and distal DH sites charac-
terized as enhancers; in human cell lines, more than 1000 interactions were observed [174].
Importantly, significant correlations were found between promoter-enhancer interactions
and gene expression. This is perhaps the most comprehensive study to have examined both
the chromatin organization of regulatory elements and their functional relationships. In con-
clusion, 3C-based methods have greatly expanded our understanding of genome structure
and mechanisms of action for distal regulatory elements such as enhancers.
1.4 TNF/LT locus and its transcriptional regulation
The TNF promoter and its distal DH sites have been shown to control transcriptional acti-
vation in response to multiple stimuli in a variety of cell types [175]. From a drug discovery
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perspective, defining the mechanisms involved in the cell type-specific control of TNF gene
expression in the context of the TNF/LT locus and its chromatin environment is critical for
the identification of novel targets for selective therapeutic modulation of TNF.
1.4.1 TNF/LT locus
The TNF/LT locus comprises the TNF, LTA, and LTB genes; their coding regions occupy
12kb on human chromosome 6p21 in a region of the major histocompatibility complex
(MHC) between class I, B (HLA-B) and class II, DR (HLA-DR) [176]. In addition to the
TNF promoter, the TNF/LT locus contains multiple DH sites [177–179]. Recent studies
by our laboratory have identified multiple constitutive and inducible DH sites that exhibit
both shared, and cell type specificity between primary human monocytes and CD4+ T cells
(unpublished results). The Goldfeld lab has labeled the distal DH sites based on their dis-
tance from the TNF TSS. For example, human hypersensitive site -12 (hHS-12) is 12kb
upstream of the TNF TSS.
hHS-12 is the most distal DH site in the TNF/LT locus and is predicted to be 200 bp in
length. It is located 12kb upstream of the TNF TSS. Examination of the site in primary
human monocytes and CD4+ T cells showed the presence of hHS-12 in monocytes but not
in CD4+ T cells. The sequence is A/T rich (65% AT).
hHS-8 (also identified as DHS44500 [178]) is located 8kb upstream of the TNF TSS and
is predicted to be 1.3kb in length. One study using ENCODE data that surveyed genome-
wide DNase I sensitivity predicted that the average non-promoter DH site is 200 to 300bp
in length [122]; thus, hHS-8 is an unusually large non-promoter DH site. In contrast to
hHS-12, hHS-8 was found in both human monocytes and CD4+ T cells. In mice, hHS-8 is
known as HSS-9 [177].
hHS-5 is located 5kb upstream of the TNF TSS and is predicted to be 300bp in length.
Like hHS-12, hHS-5 is AT-rich (59% AT) and is monocyte-specific [180]. In mice, hHS-5
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is known as HSS-7.
hHS-4 is located 4 kb upstream of the TNF TSS and is predicted to be 120bp in length.
Importantly, hHS-4 is 500bp upstream of the LTA TSS. Examination of monocytes and
CD4+ T cells showed hHS-4 to be present in CD4+ T cells and not in monocytes, support-
ing the finding that LT-α is minimally expressed in resting and activated monocytes and is
substantially expressed in activated CD4+ T cells [181]. In mice, hHS-4 is known as HSS-4
[177].
hHS+6 is located 6kb downstream of the TNF TSS and is predicted to be 200bp in
length. DHA analysis showed the site to be within the coding region of the LTB gene;
however, it is more likely to be within a non-coding region proximal to the LTB gene.
Similar to hHS-8, hHS+6 was found in both monocytes and CD4+ T cells.
hHS+8 is located 8kb downstream of the TNF TSS and is predicted to be 130bp in
length. Importantly, hHS+8 is 1kb upstream of the LTB TSS. hHS+8 is similar to hHS-4
in that it was found to be present in CD4+ T cells and not in monocytes, also supporting
the finding that LT-β is minimally expressed in resting and activated monocytes and is
substantially expressed in CD4+ T cells [181–183].
Although most of the DH sites found in the human TNF/LT locus are also found within
the mouse Tnf/Lt locus, there are a few differences. For instance, hHS-5 (murine HSS-7) is
found within the human locus but is more prominent in the murine locus, suggesting that a
smaller percentage of human cells as compared to mouse cells, on average, contain this site.
Another major difference between the murine and human locus is that one site, HSS+3, is
murine-specific. HSS+3 is 600bp in length and is found immediately downstream of the
TNF gene; it is present in both murine monocytes and CD4+ T cells [177, 180].
25
1.4.2 TNF promoter and its transcriptional regulation
Originally defined as a product of monocytes and macrophages, TNF expression has been
observed in CD4+ T cells [46], B cells [184], NK cells [48], mast cells [49], dendritic cells
[50], fibroblasts [185], and neurons [186]. In addition, TNF transcription is induced by a
number of stimuli [175], including pathogens such as bacterial LPS, viruses, and parasites;
mitogens; cytokines; and antigen binding by B cells and CD4+ T cells. Indeed, as described
below, TNF transcription is regulated in a cell type- and stimulus-specific manner.
At the level of the TNF promoter, specific sets of transcription factors and coactiva-
tors assemble to form nucleoprotein complexes known as enhanceosomes [187–189]. Both
protein-protein interactions and the conformational changes induced upon initial protein-
DNA interactions facilitate the cooperative binding of additional factors to adjacent and
overlapping sites. Additionally, coactivators that associate with multiple transcription fac-
tors can serve as “scaffold” proteins, thereby encouraging enhanceosome formation [190].
The first enhanceosome was described during the study of IFNB gene activation, and was
shown to include at least three distinct transcription factors and the high mobility group
protein HMG I(Y), which function in synergy to drive transcription [191, 192]. Each of
the transcription factors recruited to the IFNB promoter has been shown to interact with
CBP/p300, a histone acetyltransferase known to acetylate histones and non-histone pro-
teins. In addition to acetylating histones within the IFNB promoter, CBP/p300 is thought
to function as a scaffold protein, facilitating enhanceosome assembly [193].
Enhanceosome formation at the TNF promoter is particularly complex by comparison in
that it has been shown to occur in a cell type- and inducer-specific fashion. The proximal
TNF promoter maps to a highly conserved region 200bp proximal to the TNF TSS, and
is sufficient for transcriptional activation in response to multiple stimuli [189, 194–196].
Within the TNF promoter, there is a TATA box and multiple transcription factor binding
sites, including six nuclear factor of activated T cells (NFAT) sites, four Ets/Elk-1 sites, two
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Sp1 sites, an Egr site, and an ATF-2/c-Jun site [175] (Figure 1.4.1). In T cells, enhanceo-
some formation was found to be inducer-specific; ionomycin, which increases intracellular
Ca2+ levels, was shown to promote NFAT binding to all six NFAT sites whereas Sendai
virus infection was shown to promote less NFAT binding than ionomycin [187]. Differen-
tial NFAT binding at the promoter was partly due to differences in regional NFAT concen-
tration, as more NFAT translocates into the nucleus upon ionomycin stimulation than after
viral infection [187]. In addition, Sp1 binding was observed to a much larger extent at the
-55NFAT/Sp1 site after Sendai virus infection as compared to ionomycin stimulation, and
was shown to synergize with NFAT and ATF-2/c-Jun [198]. Importantly, the -55NFAT/Sp1
site is a fairly weak Sp1 site; thus Sp1 is outcompeted in scenarios of high NFAT levels
like ionomycin stimulation. In conclusion, TNF transcription in T cells provides a striking
example of stimulus-specific gene regulation that encompasses both regional concentration
of specific transcription factors and affinities of binding sites.
In the case of monocytes and macrophages, LPS stimulation results in the formation
of an enhanceosome that is distinct from that found in T cells in response to ionomycin
treatment or Sendai virus infection. In particular, two Sp1 sites, four Ets/Elk-1 sites, an
ATF-2/c-Jun site, and an Egr binding site were found to be critical for LPS induction of TNF
transcription in macrophages [189]. Notably, Ets and Elk-1 proteins were found in place of
NFAT at the TNF promoter upon LPS stimulation. Thus, the presence of overlapping DNA
motifs that can serve as both NFAT and Ets/Elk-1 binding sites allows for a broad spectrum
of distinct enhanceosomes to form at the TNF promoter depending on cell type and the
signaling pathways triggered. Interestingly,M. tuberculosis induction of TNF transcription
in macrophages involves an enhanceosome of similar composition to that of LPS induction
[195].
In the case of LPS stimulation in monocytes and macrophages, some initial studies sug-
gested a role for the transcription factor NF-κB, which is now known to play a key role in
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Figure 1.4.1: Cell type- and inducer-specific enhanceosome formation at the proximal TNF promoter. (a) Se-
quence of human proximal TNF promoter showing the positions of transcription factor binding sites. (b) Tran-
scription factors that bind at sites in the indicated cell types and in response to the indicated stimuli. (c) Model of
inducer-specific enhanceosome formation at the proximal TNF promoter in T cells and monocytes. [175, 195, 197].
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TLR signaling. Multiple NF-κB sites lie upstream of the TNF TSS, but these are generally
not conserved betweenmice and humans and lie outside of the proximal promoter [196, 199,
200]. The one NF-κB-like site present in the proximal promoter, originally designated κ3
[196], is bound by NFAT proteins and functions as a calcineurin-dependent composite ele-
ment within the adjacent CRE site. This site binds ATF-2/c-Jun heterodimer, and is required
for TNF transcription in response to multiple stimuli [187, 189, 194, 195, 198, 201–206].
Through EMSA and quantitative DNase I footprinting analysis, recombinant p50/p65 was
shown not to bind specifically to κ3 or any other site within the proximal TNF promoter. In
addition, assays targeting NF-κB activity in monocytes and macrophages indicated a post-
transcriptional induction of NF-κB in response to LPS for maintaining TNF mRNA levels
in these cells, rather than a direct role in initiation of TNF transcription [207].
As stated previously, a primary function of transcription factors is to promote the re-
cruitment of nucleosome remodeling enzymes to regulatory regions, thereby promoting
chromatin accessibility and subsequent binding of RNA Pol II. Importantly, CBP/p300 has
been shown to play a major role in TNF transcription in both macrophages and T cells
[188, 189, 195]. Inhibition of CBP/p300 impairs TNF transcription induced by LPS in
murine macrophages [188]. Strikingly, examination of splenic T cells from Cbp+=  mice
showed that induction of TNF transcription by TCR engagement was dramatically reduced
as compared to what is found in cells isolated from wild-type or p300+=  mice, indicating
a novel inducer-specific role for CBP in TNF enhanceosome formation in activated T cells
[188]. This conclusion was indeed supported by later findings in conditional knockout mice
[208]. Together, these studies demonstrate the importance for CBP/p300 in TNF transcrip-
tional activation and support a model where CBP/p300 acts as a “scaffold” protein during
enhanceosome formation at the TNF promoter.
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1.4.3 Distal regulatory elements at the TNF/LT locus
As stated previously, multiple DH sites distal to the TNF promoter lie within the TNF/LT lo-
cus. Importantly, many of the identified DH sites coincide with regions of highly conserved
DNA, which suggests regulatory function. From an evolutionary perspective, functionally
relevant sequences are typically subjected to negative selection, whereas non-functional
sequences are subject to genetic drift and become increasingly different between species
with increasing phylogenetic distance [209]. Thus, highly conserved non-coding DNA se-
quences are predicted to be regulatory elements. Extending the findings of conserved func-
tional noncoding DNA sequences in the TNF promoter [197, 199, 210], other DH sites in
the TNF/LT locus, including hHS-8, were found to be strongly conserved between mice and
humans, as well as a number of other species [178].
DH sites within the murine Tnf/Lt locus have been shown to undergo inducible intrachro-
mosomal interactions while functioning as enhancers. Increased levels of H3ac and H4ac
were found at both HSS-9 and HSS+3 in murine T cells in response to anti-CD3/CD28 acti-
vation, suggesting inducible chromatin remodeling at these distal sites in the murine Tnf/Lt
locus [177]. In addition, both HSS-9 and HSS+3 were shown to enhance Tnf promoter
activity in a murine T cell line in an NFAT-dependent manner. Finally, it was demonstrated
through 3C analysis that an inducible intrachromosomal interaction between the Tnf pro-
moter, HSS-9, and HSS+3 occurred upon activation of murine T cells. Thus, the interplay
of histone modifications, transcription factor binding, and intrachromosomal interactions
orchestrate inducible enhancer function at the murine Tnf/Lt locus, allowing for rapid and
potent activation of this critical immunological factor during innate immune responses.
30
1.5 Summary of Aims
Macrophages are fundamental cellular components of the innate immune response. Al-
though the genetic programs and signal transduction pathways that contribute tomacrophage
activity in response to microbial infection have been thoroughly investigated, much less is
known about the chromatin-remodeling factors and related chromatin environment that or-
chestrate these cellular processes. The overarching goal of this thesis project was to identify
and dissect mechanisms of chromatin remodeling that control classical macrophage activa-
tion and endotoxin tolerance. To achieve this goal we used the TNF/LT locus as our model
system. This locus encodes TNF, the archetypical inflammatory cytokine whose enhance-
ment and repression is representative of classical macrophage activation and endotoxin tol-
erance, respectively.
Our first aim was to test the hypothesis that potent TNF gene expression in response to
classical macrophage activation, where a priming signal by IFN-γ results in augmentation
of TNF gene expression upon LPS stimulation, is regulated, at least in part, by IFN-γ-
mediated chromatin modifications at the TNF/LT locus. Findings from experiments de-
signed to address this hypothesis are described in Chapter 2. Our second aim was to test the
hypothesis that chromatin modifications at the TNF/LT locus are also critical for the modu-
lation of TNF gene expression during the induction of endotoxin tolerance in macrophages,
and that the ability of IFN-γ to restore LPS-induced TNF gene expression in endotoxin-
tolerant macrophages depends on similar chromatin changes as those induced by IFN-γ at
the TNF/LT locus during macrophage priming. In Chapter 3, we present findings from
experiments performed to address this hypothesis.
A diverse array of experimental techniques were employed to achieve the overall goal of
this project, including DNase I hypersensitivity analysis, DNase I footprinting, chromatin
immunoprecipitation (ChIP), and genetic knockdown and mouse knockout systems. The
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experiments were performed, when possible, using primary human macrophages in order to
obtain data of clinical relevance. The findings described in this dissertation provide novel
insights into mechanisms of chromatin remodeling at play during macrophage priming,
induction of endotoxin tolerance, and abrogation of endotoxin tolerance. We expect these
findings to be broadly applicable to other primary response genes that are similarly affected
by these biological processes. In addition, we anticipate that the findings described herein
will provide a foundation for future research efforts aimed at defining and manipulating
cellular targets that are critical for the regulation of TNF gene expression in the context
of i) an innate immune response, and ii) the excessive inflammation found in autoimmune
diseases.
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Chapter 2
IFN-γ priming of LPS-mediated TNF gene expression occurs
via inducible IRF1 binding and histone methylation at a highly
conserved distal enhancer
2.1 Introduction
During infection, antigen-presenting cells secrete IL-12, which helps link innate and adap-
tive immunities by promoting the differentiation of naïve CD4+ T cells toward a Th1 phe-
notype and by inducing IFN-γ secretion from NK cells and activated CD4+ T cells [211].
Accordingly, IFN-γ sensitizes surrounding macrophages to microbial recognition and, most
notably, augments the production of TNF [44, 59]. This phenomenon of IFN-γ-mediated
macrophage sensitization is known as IFN-γ priming. In vitro, maximum effects of IFN-γ
priming have been shown to occur within two hours of IFN-γ pre-treatment, resulting in
enhanced mRNA levels of TNF [212] and of other cytokines and inflammatory molecules
such as IL-12 [60], IL-6 [57], and NO [58] upon LPS stimulation.
The mechanisms involved in priming are unclear; the IFN-γ-inducible transcription fac-
tors IRF1 and STAT1 have been implicated [84, 213], but functional roles for these factors
have not been determined. One study examining the effect of IFN-γ on chromatin modifica-
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tions at the TNF promoter observed increased levels of H4ac in primary human monocytes
treated with IFN-γ as compared to resting cells [214]. In addition, a recent study has shown
H3K27ac enrichment at both the TNF promoter and a distal DH site during IFN-γ priming
[213]. In the context of IFN-γ priming, functional roles for distal DH sites in the TNF/LT
locus have not been demonstrated.
Here, we show that IFN-γ priming of TNF transcription requires functional binding of
IRF1 to the distal TNF enhancer element hHS-8. IFN-γ also poises hHS-8 for enhancer
function by increasing levels of H3K27me3. Subsequent LPS stimulation triggers hHS-8
enhancer activation by first demethylating and then acetylating H3K27. These experiments
provide a mechanistic explanation for IFN-γ priming of the LPS response using TNF as a
model system, while at the same time providing potential targets for selective manipulation
of TNF overexpression in primed macrophages.
2.2 Results
2.2.1 IFN-γ primes monocytes and macrophages for enhanced TNF gene expression.
IFN-γ priming dramatically enhances TNF gene expression in LPS-induced monocyte and
macrophage activation. We first observed the effect of IFN-γ priming in THP-1 cells, a
human monocytic cell line, by pretreating cells with IFN-γ 2h before LPS stimulation and
found a two-fold increase in TNF mRNA levels as compared to that of LPS alone (Figure
2.2.1a). To verify that enhanced TNF gene expression results in enhanced protein produc-
tion, we measured TNF protein levels in supernatant and again found a two-fold increase
in cells pretreated with IFN-γ as compared to cells treated with LPS alone (Figure 2.2.1b).
We also verified that IFN-γ priming is not LPS specific by showing enhanced TNF expres-
sion in monocytes activated with whole lysate from M. tuberculosis strain H37Rv (Figure
2.2.1c). We next confirmed this phenomenon in primary human MDMs activated by LPS
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(Figure 2.2.1d). Despite significant differences in morphology and function between mono-
cytes and macrophages, IFN-γ synergizes with LPS in both cell types to enhance TNF gene
expression at the transcriptional level, suggesting that IFN-γ affects the chromatin environ-
ment at the TNF/LT locus in a similar mechanism for both cell types. When proposing a
mechanism for IFN-γ priming, we take note that both monocytes and macrophages treated
with IFN-γ alone induced minimal levels of both TNF mRNA and protein and were com-
parable to untreated samples; thus, we hypothesized that although IFN-γ does not induce
TNF transcription, it poises the TNF/LT locus for enhanced transcription in response to LPS
stimulation.
2.2.2 IFN-γ promotes chromatin accessibility at hHS-8 in the TNF/LT locus.
We next looked at the ability of IFN-γ to remodel the TNF/LT locus by performing DNase
I hypersensitivity assays (DHAs), and found that IFN-γ promotes DNase I cleavage at the
human hypersensitive site, hHS-8. DHAs utilize the ability of DNase I to distinguish and
cleave accessible DNA in packaged chromatin. DNA from both THP-1 cells and primary
humanMDMs stimulated with IFN-γwere partially digested with DNase I. BamHI and ScaI
digestion allowed for visualization of the TNF promoter and hHS-8, respectively (Figure
2.2.2a). When comparing untreated and IFN-γ treated THP-1 cells, minimal differences in
DNase I accessibility at the TNF promoter were observed. This is evidenced by similar band
intensities between untreated and IFN-γ treated samples (Figure A.0.1a, lane 4 compared to
lane 8). However, we detected a strongly enhanced band corresponding to hHS-8 from cells
treated with IFN-γ as compared to untreated cells (Figure A.0.1b, lane 4 compared to lane
8). Results were repeated in primary human MDMs for both the TNF promoter and hHS-8
(Figures 2.2.2b, lane 3 compared to lane 6; 2.2.2c, lane 3 compared to lane 6). Thus, when
thinking of a population of monocytes or macrophages, hHS-8 is constitutively present in
a given percentage of cells, and, upon IFN-γ stimulation, the percentage of cells exhibiting
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Figure 2.2.1: IFN-γ primes monocytes and macrophages for enhanced TNF gene expression. (a) THP-1 cells
were stimulated with IFN-γ alone for 3h, LPS alone for 1h, and both IFN-γ and LPS (IFN-γ pretreatment for 2h
followed by LPS treatment for 1h), and TNF mRNA levels were measured post LPS stimulation. (b) THP-1 cells
were stimulated as in (a), and TNF protein levels in supernatants were measured by ELISA post LPS stimulation.
(c) THP-1 cells were stimulated with IFN-γ alone for 3h, MTb lysate alone for 1h, and both IFN-γ and MTb lysate
(IFN-γ pretreatment for 2h followed by MTb lysate treatment for 1h), and TNF protein levels in supernatants were
measured as in (b). Data from 1 experiment. (d) Primary human MDMs were treated as in (a), and TNF mRNA
levels were measured 1h post LPS stimulation. Data from 3 donors. (*) p  0:05, (**) p  0:01, and (***)
p  0:001.
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accessibility at hHS-8 significantly increases in the population.
In addition to DNase I accessibility, we analyzed nucleosome occupancy at the TNF
promoter and hHS-8 by measuring total H3 levels by ChIP. As expected, we observed a
significant loss in total H3 levels at the promoter in response to LPS stimulation (Figures
2.2.2d, 2.2.2e). We also observed a significant loss in total H3 levels at hHS-8 in response
to IFN-γ and LPS stimulation (Figure 2.2.2d). Results were repeated in primary human
MDMs isolated from a representative donor (Figure 2.2.2e). This data correlates with our
finding that increased DNase I cleavage occurs at hHS-8 in response to IFN-γ treatment.
Together, we show that IFN-γ poises the TNF/LT locus by exposing hHS-8, a hypersensitive
site distal to the TNF promoter.
2.2.3 IRF1 binds to the TNF promoter and hHS-8 in an IFN-γ-inducible manner.
Increased chromatin accessibility often predicts binding of transcription factors and/or coac-
tivators. We next sought to identify factors binding to the TNF/LT locus in an IFN-γ-
inducible manner. Given that IFN-γ is a potent inducer of the transcription factor IRF1
[215] (Figure A.0.2), we investigated whether IRF1 binds to specific sequences within the
TNF/LT locus, particularly at known DH sites. We scanned all DH sites for potential IRF
binding sites similar to its consequence sequence (5’-AANNGAAANGAA-3’) [82] and
verified by both in vitro and in vivo methods that IRF1 binds to both the TNF promoter
and hHS-8. Past studies have shown cell type- and inducer-specific recruitment of specific
sets of transcription factors and coactivators to the proximal region of the TNF promoter
(Figure 2.2.3a).
Quantitative DNase I footprinting analysis reveals where factors bind to DNA with the
resolution of a single nucleotide. We observed that recombinant IRF1 (rIRF1) binds to the
TNF promoter in a region 50bp in length (Figure 2.2.3b). Notably, this is the same region
where transcription factors Sp1, Egr1, and NFAT have been shown to bind, which further
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Figure 2.2.2: IFN-γ promotes chromatin accessibility at hHS-8 in the TNF/LT locus. (a) Map of the human TNF/LT
locus. DH sites and positions and directions of transcription of the TNF, LTA, and LTB genes are shown. Positions
of the parental ScaI, parental BamHI, and DNase I digestion products for the DHAs are indicated; fragment repre-
senting DNase I accessibility at the TNF promoter and hHS-8 is 3kb and 5kb in length, respectively. (b) IFN-γ does
not affect DNase I cleavage at the TNF promoter. DHA using primary human MDMs. (c) IFN-γ strongly increases
DNase I cleavage at hHS-8. (d) IFN-γ and LPS decrease nucleosome occupancy at the TNF promoter and hHS-8.
ChIP using THP-1 cells (d) and primary human MDMs, 1 donor (e) measures total H3 levels. (*) p  0:05 and
(***) p  0:001. 38
emphasizes the complexity of cell-type and inducer-specific regulation of TNF transcription
(Figure 1.4.1). In addition to the TNF promoter, we observed that rIRF1 occupies a region
in hHS-8 that is also 50bp in length and contains four -GAAA-motifs, suggesting multiple
tandem IRF1 binding sites (Figure 2.2.3c). Other in vitro assays using human T cells have
shown binding of NFAT to regions near the newly identified IRF1 binding site (Figure
2.2.3a).
We next investigated whether IRF1 is recruited to the promoter and hHS-8 in an IFN-γ
inducible manner. ChIP studies using primary human MDMs confirmed that upon IFN-γ
stimulation, IRF1 is massively recruited to hHS-8 within the same region as identified by
footprinting analysis and, to a lesser extent, to the TNF promoter (Figure 2.2.3d). Thus,
upon IFN-γ stimulation, hHS-8 has a higher affinity for IRF1 than the TNF promoter. We
speculated that IRF1 recruitment to both the TNF promoter and hHS-8 is important for the
ability of IFN-γ to prime both monocytes and macrophages.
2.2.4 IRF1 is required for enhanced TNF expression in IFN-γ-primed monocytes and
macrophages.
We next tested whether IRF1 plays a functional role in IFN-γ-induced enhancement of TNF
gene expression. Using bonemarrow-derivedmacrophages (BMDMs) from IRF1-deficient
(Irf1-/-) mice, we show that IRF1 is required for enhanced TNF gene expression in murine
macrophages primed with IFN-γ. We isolated BMDMs from wild-type and Irf1-/-mice and
measured TNF protein levels in response to IFN-γ and LPS.We observed no significant dif-
ferences in TNF protein levels betweenwild-type and Irf1-/-mice stimulatedwith IFN-γ and
LPS alone. As seen in THP-1 cells and primary humanMDMs, wild-type BMDMs secreted
significantly higher levels of TNF protein when primed with IFN-γ than when treated with
LPS alone (Figure 2.2.4a). However, we did not observe enhancement in Irf1-/- BMDMs
(Figure 2.2.4b); thus, we conclude that IRF1 is required for IFN-γ-induced enhancement of
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Figure 2.2.3: IRF1 binds to the TNF promoter and hHS-8 in an IFN-γ-inducible manner. (a) Human TNF/LT locus
with partial sequences of both the TNF promoter and hHS-8 and positions of transcription factor binding sites. (b)
rIRF1 binds to the TNF promoter. Quantitative DNase I footprinting analysis of the TNF promoter (-200 to +1) and
increasing concentrations of rIRF1. Sense and anti-sense strand with G/A ladder and BSA control. Bars mark
areas of rIRF1 binding at -172 to -136. (c) rIRF1 binds to hHS-8. Analysis of hHS-8 (-7031 to -6782); bars mark
areas of rIRF1 binding at -6833 to -6782. (d) IRF1 is recruited to both the TNF promoter and hHS-8 in an IFN-γ-
inducible manner. ChIP using primary human MDMs and analyzing IRF1 recruitment, data from 3 separate donors.
(*) p  0:05 and (**) p  0:01.
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TNF gene expression.
In addition to murine BMDMs, we looked at the ability of IFN-γ priming to enhance TNF
gene expression in humanmonocytes treated with shRNA targeting IRF1. THP-1 cells were
transfected with either shRNA targeting human IRF1 or control shRNA encoding a scram-
bled sequence. Sufficient knockdown of IRF1mRNAwas observed when cells were treated
with IFN-γ for 3h (Figure 2.2.4c), which we concluded as sufficient knockdown of IRF1
protein considering its extreme instability (half-life 30min) [216, 217]. As expected, we
observed significant enhancement of TNF mRNA levels in IFN-γ primed THP-1 cells ex-
pressing control shRNA. In contrast, enhancement of TNFmRNA levels was lost in primed
THP-1 cells expressing IRF1 shRNA (Figure 2.2.4d). These data indicate that IRF1, which
we have shown to be massively recruited to hHS-8 upon IFN-γ stimulation, is necessary for
enhanced TNF gene expression in both murine macrophages and human monocytes primed
with IFN-γ. Indeed, the IRF family comprises nine transcription factors that all share similar
consensus sequences [82]; however, this data suggests that other IRFs are not functionally
redundant to IRF1 in the context of IFN-γ priming.
2.2.5 hHS-8 functions as an IFN-γ-inducible, IRF1-dependent enhancer of TNF transcrip-
tion.
We speculated that hHS-8 might function as an IFN-γ-inducible regulatory element dur-
ing IFN-γ priming of monocyte and macrophage activation. Specifically, we hypothesized
that hHS-8 functions as an IFN-γ-inducible enhancer of TNF transcription, and that IRF1
plays a role in the ability of hHS-8 to function as an enhancer. We first analyzed sequence
conservation at the IRF1 binding sites within hHS-8 and found these sites to be highly con-
served among the great apes, small apes, old world monkeys, and new world monkeys.
High sequence conservation within non-coding regions of DNA infers regulatory function
[209]. We compared the human sequence to those of non-human primate species and sub-
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Figure 2.2.4: IRF1 is required for enhanced TNF expression in IFN-γ-primed monocytes and macrophages. (a,b)
Enhanced TNF gene expression induced by IFN-γ priming is abrogated in IRF1-deficient murine BMDMs. Wild-
type (a) and Irf1-/- (b) BMDMs were stimulated, and TNF protein levels in supernatants were measured by ELISA
post LPS stimulation. Data from 3 separate experiments each with N = 3. (c) THP-1 cells that constitutively
express lentivirally-delivered shRNA targeting IRF1 or control shRNA encoding a scrambled sequence were stimu-
lated with IFN-γ alone for 3h, and IRF1 mRNA levels were measured. (d) Enhanced TNF gene expression induced
by IFN-γ priming is abrogated in human monocytes where IRF1 expression is silenced. THP-1 cells expressing
IRF1 and control shRNA were stimulated, and TNF mRNA levels were measured (shown relative to LPS values).
(*) p  0:05 and (***) p  0:001.
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species including multiple individuals representing species of the great apes [chimpanzee
(Pan troglodytes), gorilla (Gorilla), and orangutan (Pongo)], the small apes [two genera of
gibbon (Hylobatidae andNomascus)], the old world monkeys [macaque (Macaca), Chloro-
cebus, andPapio] and the newworldmonkeys [Callithrix and Lagothrix]. We found that the
core -GAAA- motifs of the IRF1 binding sites in hHS-8 are completely conserved among
human and all non-human primate species analyzed (Figure 2.2.5a), which suggests the
presence of phylogenetic footprints in hHS-8. High sequence conservation among pri-
mates is similarly seen in the TNF promoter where multiple binding sites for transcrip-
tion factors and coactivators are involved in highly coordinated cell type- and inducer-
specific enhanceosome formation [197, 210]. Notably, analysis of IRF1 binding sites in
HSS-9 (murine hHS-8) showed two differences in the core -GAAA- motifs (Figure 2.2.5a).
Through EMSA analysis, we demonstrated that the differences in the mouse sequence do
not impact IRF1 binding (Figure A.0.3, lane 2 compared to lane 4).
In order to test whether hHS-8 functions as an inducible enhancer of TNF transcription,
we cloned the hHS-8 sequence (Figure A.0.4) into a reporter vector where luciferase ex-
pression is driven by the TNF promoter. We transiently co-transfected the constructs with
pRL-TK (Renilla luciferase, internal control) into the murine macrophage cell line J774
and stimulated cells accordingly. Luciferase activity was measured by a dual-luciferase
reporter assay. In macrophages primed with IFN-γ, the presence of hHS-8 significantly
enhanced the ability of the TNF promoter to drive luciferase expression in response to LPS,
confirming that hHS-8 functions as an IFN-γ-inducible enhancer.
In order to assess the importance of IRF1 in hHS-8 enhancer function, we also mutated all
four highly conserved IRF1 -GAAA- motifs to -GAGG-, which we showed by EMSA anal-
ysis to completely disrupt IRF1 binding (Figure 2.2.5b). Mutation of the IRF1 binding sites
in hHS-8 abolished its ability to enhance TNF promoter activity in macrophages primed by
IFN-γ and induced by LPS (Figure A.0.5); thus, we conclude that hHS-8 functions as an
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IRF1-dependent inducible enhancer of TNF transcription in macrophages primed by IFN-γ.
Understanding the functional importance of IRF1 binding to the TNF promoter is compli-
cated by the fact that LPS induced TNF transcription requires intact Sp1 and Egr binding
sites [189] that were found to coincide with the IRF1 binding sites (Figure 2.2.3a). Thus,
we only examined the functional importance of IRF1 binding to hHS-8.
2.2.6 H3K27me3 and H3K27ac play a critical role in IFN-γ priming.
H3K27me3 and H3K27ac have been shown to distinguish active and inactive enhancers in
mouse and human embryonic stem cells [218–220]. We hypothesized that IFN-γ priming
and LPS stimulation affect H3K27me3 and H3K27ac levels at hHS-8. ChIP studies using
THP-1 cells showed that upon IFN-γ stimulation, levels of H3K27me3 increased at hHS-
8, whereas levels at the TNF promoter remained constant (Figure 2.2.6a). Cells that were
primed with IFN-γ and then stimulated with LPS were not enriched for H3K27me3 at hHS-
8, suggesting that H3K27me3 marks hHS-8 during priming and is lost upon TNF gene
activation. Enrichment of H3K27ac was also shown to be inducible; levels of H3K27ac
significantly increased at hHS-8 in cells primed by IFN-γ and stimulated with LPS (Figure
2.2.6b). Notably, H3K27ac enrichment at hHS-8 did not occur in cells treated with LPS
alone, demonstrating a requirement of IFN-γ priming for H3K27ac enrichment at hHS-8.
H3K27ac levels at the TNF promoter dramatically increased upon stimulation with LPS
alone, which supports the finding of LPS-induced CBP/p300 recruitment to the TNF pro-
moter in monocytes and macrophages [189].
Next, we investigated the reciprocal nature of H3K27me3 and H3K27ac at hHS-8 and
whether the marks were important for enhanced TNF gene expression in the context of IFN-
γ priming. To do this, we inhibited the H3K27me3-specific demethylases JMJD3 and UTX.
THP-1 cells were first primed by IFN-γ and then treated with either GSK-J4 [147] (active
inhibitor of JMJD3 and UTX) or GSK-J5 [147] (inactive inhibitor) 30min before the LPS
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Figure 2.2.5: hHS-8 functions as an IFN-γ-inducible, IRF1-dependent enhancer of TNF transcription. (a) IRF1
binding sites (nucleotides -6833 to -6784) in hHS-8 are highly conserved among all primate species examined.
Critical -GAAA- motifs for IRF1 binding are highlighted. (b) Disruption of IRF1 binding to hHS-8 abolishes inducible
enhancer function and thus enhanced TNF transcription induced by IFN-γ priming. Constructs were transfected
into J774 cells and stimulated with IFN-γ alone for 8h, LPS alone for 6h, and both IFN-γ and LPS (IFN-γ pretreat-
ment for 2h followed by LPS treatment for 6h). “TNF” is the TNF promoter and “hHS-8” is the entire sequence of
hHS-8 (1250bp in length), and “muthHS-8” is hHS-8 with mutations that disrupt IRF1 binding. (***) p  0:001.
45
stimulations (Figure 2.2.6c). Notably, THP-1 cells are deficient in UTX expression [221]
and thus serve as an effective model system for understanding the effects of specifically
inhibiting JMJD3 with the compound. In cells treated with GSK-J5, we observed effective
IFN-γ priming, evidenced by enhanced TNF mRNA levels upon LPS induction (Figure
2.2.6d). In contrast, IFN-γ priming failed to enhance TNF mRNA levels in cells treated
with GSK-J4, demonstrating a critical role for H3K27me3 in IFN-γ priming and the abil-
ity to enhance TNF transcription. We hypothesize that IFN-γ poises hHS-8 for enhancer
function through mechanisms that involve IRF1 recruitment and H3K27me3 enrichment.
Subsequent LPS stimulation activates hHS-8 enhancer function through mechanisms that
first demethylate and then acetylate H3K27.
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Figure 2.2.6: H3K27me3 and H3K27ac play a critical role in IFN-γ priming. (a) IFN-γ increases H3K27me3 preva-
lence at hHS-8. ChIP using THP-1 cells and analyzing H3K27me3 prevalence at the TNF promoter and hHS-8.
(b) Activation of hHS-8 enhancer function corresponds with increased H3K27ac prevalence at hHS-8. ChIP using
THP-1 cells and analyzing H2K37ac prevalence at the TNF promoter and hHS-8. (c) Chemical structures of the
active JmjD3/UTX inhibitor (GSK-J4) and the inactive inhibitor (GSK-J5). (d) Inhibition of H3K27me3 demethylation
prevents enhanced TNF gene expression induced by IFN-γ priming. THP-1 cells were treated with either the GSK-
J5 or GSK-J4 compound (30uM) 30min before LPS stimulations, and TNF mRNA levels were measured (shown
relative to LPS values). (*) p  0:05 and (**) p  0:01.
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2.3 Discussion
One of the most important functions of IFN-γ is to prime monocytes and macrophages
thereby ensuring an enhanced response to microbial activation. The mechanism of IFN-γ
priming has been investigated for IL-12 [84] and IL-6 [57], and in both cases, transcriptional
regulation has been confined to the promoter. Considering the importance of TNF and its
dysregulation in the pathology of several inflammatory disorders, we sought to determine
the mechanism for IFN-γ-induced priming of TNF gene expression. Here, we observe tran-
scriptional regulation by IFN-γ to be beyond the promoter by demonstrating a critical role
for an inducible enhancer distal to the TNF TSS. In addition to showing a prominent role
for IRF1 in enhancer function, we observe H3K27me3 marking a poised enhancer in an
adult somatic cell in the context of immune signaling.
Spanning 1.3kb, hHS-8 is nearly five times larger than the average non-promoter DH
site [122], and we have shown functional IRF1 recruitment to its most highly conserved
region. We do expect hHS-8 enhancer function to additionally involve the recruitment of
coactivator proteins and multiple lineage-specific transcription factors. Indeed, studies in
murine T cells have shown NFAT binding to HSS-9 [177]. Considering the necessity of
IRF1 for enhanced TNF gene expression in primed monocytes and macrophages, we won-
der whether IRF1 functions as a pioneer factor. First identified in yeast, pioneer factors
are transcription factors that bind to DNA and recruit chromatin-remodeling complexes
thereby promoting the recruitment of other factors to their corresponding DNA sequences
that otherwise would have been inaccessible [165]. Additional binding studies in mono-
cytes and macrophages are required in order to properly assess whether IRF1 functions as
a pioneer factor. Indeed, IRF1 has been reported to interact with the histone acetyltrans-
ferase, CBP/p300 [222]. In addition, we have shown by ChIP analysis that p300 is recruited
to hHS-8 upon LPS stimulation in primary human MDMs (Figure A.0.6). We can imagine
48
a situation where IFN-γ utilizes IRF1 to recruit CBP/p300 to hHS-8; CBP/p300, along with
the aid of other factors, could induce chromatin-remodeling events necessary for enhancer
activation.
Enhancers are often characterized by chromatin signatures such as increased chromatin
accessibility, enrichment of specific histone modifications like H3K4me1 and H3K27ac,
prevalence of RNA Pol II, presence of histone variants H3.3 and H2A.Z, and increased
prevalence of ATP-dependent chromatin remodeling complexes like CBP/p300 [223]. Re-
cent studies in embryonic stem cells have shown that only a fraction of elements marked
by H3K4me1 are actively engaged in enhancing transcription; thus, H3K4me1 does not
distinguish between active and inactive/poised enhancers. The presence of H3K27ac has
been extensively shown in both human and mouse embryonic stem cells to separate ac-
tive from poised enhancers [218]. Specifically, active enhancers are enriched for H3K27ac
while poised enhancers lack H3K27ac enrichment. In addition to lacking H3K27ac, poised
enhancers have been shown, most often, in pluripotent cells to be enriched for H3K27me3
[219, 220]. Here, we show that in an adult somatic cell, IFN-γ marks a poised enhancer in
the TNF/LT locus with H3K27me3 thereby supporting the finding that H3K37me3 enrich-
ment at poised enhancers is not limited to pluripotent cells. We also show that upon LPS
stimulation, levels of H3K27me3 are significantly decreased at hHS-8; this is followed by
an enrichment of H3K27ac, which suggests enhancer activation.
What then is the mechanism for LPS-induced removal of H3K27me3 and addition of
H3K27ac at hHS-8? We hypothesize that the same factor(s) responsible for demethylating
H3K27 form a complex with the factor(s) responsible for acetylating H3K27. Interestingly,
a study in Drosophila showed that UTX physically associated with CBP in vivo [224], sug-
gesting that the individual activities of demethylating and acetylating H3K27 are function-
ally coupled. We hypothesize that upon LPS stimulation, complexes containing JMJD3
(or UTX) and CBP/p300 associate with hHS-8 and effectively demethylate and acetylate
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H3K27 residues. This in turn is essential for hHS-8 enhancer activation.
In addition, investigating whether IRF1 recruitment to hHS-8 plays a functional role in
the enrichment of H3K27me3 and H3K27ac may provide novel insights regarding the role
of transcription factors in enhancer activation. ChIP analysis of H3K27me3 and H3K27ac
in primed monocytes and macrophages where IRF1 expression is knocked down could pro-
vide insight into the many functions of IRF1. We would like to note that GSK-J4 targets
global H3K27me3 demethylation and that it is difficult to understand the effects of this
modification at one particular region of DNA. Thus experiments targeting the disruption of
H3K27me3 demethylation specifically at hHS-8 would need to be employed.
In our model, we predict the formation of an IRF1-dependent intrachromosomal interac-
tion at the TNF/LT locus between the promoter and hHS-8 upon TLR-induced activation
in monoctyes and macrophages primed by IFN-γ. The mechanism(s) of action on promot-
ers for enhancers has yet to be determined. The predominant model known as the “loop-
ing” model predicts a direct interaction between the promoter and enhancer resulting in
the displacement or “looping out” of the intervening DNA [169]. Using chromosome con-
formation capture (3C) assay, an inducible intrachromosomal interaction between HSS-9,
HSS+3, and the TNF promoter was demonstrated in murine T cells [177]. Unfortunately,
we were unable to successfully perform the 3C assay using our model system. Other, less
robust techniques suggesting a direct interaction between a promoter and enhancer involve
Pol II occupancy at the enhancer. We have yet to investigate whether Pol II is recruited
to hHS-8 upon TLR-activation in monoctyes or macrophages primed by IFN-γ. Other po-
tential mechanisms of enhancer action include enhancer RNAs (eRNAs) [225]. eRNAs
are transcripts that are products of transcription at Pol II-associated enhancers; they can
either by polyadenylated or non-polyadenylated. The fact that not all enhancers are tran-
scribed implies functional differences between transcribed and non-transcribed enhancers.
It is thought that transcription of enhancers, similar to H3K27ac enrichment, might mark
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active enhancers; however, the functional roles, if any, for eRNAs are unknown. It is of
interest to investigate whether hHS-8 is transcribed.
In conclusion, our identification of critical protein-DNA interactions and inducible his-
tone modifications during IFN-γ priming of LPS-induced TNF transcription not only pro-
vides a mechanism of IFN-γ priming but also provides potential therapeutic targets to con-
trol TNF dysregulation. Future studies will characterize additional factors and interactions
that regulate this vital immune process.
2.4 Materials and Methods
Cell culture and stimulations
THP-1 cells were maintained in RPMI-1640 supplemented with 10% FBS. J774 cells
were maintained in DMEM supplemented with 10% FBS. For primary human MDMs, en-
riched populations of human monocytes were isolated from healthy human donor buffy
coats using a CD14+ positive selection kit (Stemcell). MDMs were obtained after 6d of
culture in RPMI-1640 medium supplemented with 5% human serum AB (Gemcell) and
GM-CSF (50ng/ml; Peprotech). Cells were treated with IFN-γ (100ng/ml; R&D) and LPS
(100ng/ml; Sigma E. coli O111:B4). GSK-J4 and GSK-J5 compounds [147] were gener-
ously supplied by GlaxoSmithKline, resuspended in DMSO, and used at a final concentra-
tion of 30μM.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted from cells with a QuickRNAMini kit (Zymo) and treated with
Turbo DNA-free kit (Invitrogen). cDNAwas synthesized from total RNA with M-MLV re-
verse transcriptase (Invitrogen) and 20-residue oligo (dT) (Invitrogen). TNF mRNA levels
were measured by the change-in-threshold (ΔΔCt) method based on quantitative real-time
PCR in an iCycler iQ (Bio-rad) with SyberGreen Master Mix (Invitrogen) and primers rec-
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Table 2.4.1: Primer sequences.
Primer Sequence
Human TNF exon 4 (F) TCTTCTCGAACCCCGAGTGA
Human TNF exon 3 (R) CCTCTGATGGCACCACCAG
Human GapdH (F) GGTGGTCTCCTCTGACTTCAACA
Human GapdH (R) GTTGCTGTAGCCAAATTCGTTGT
Human IRF1 (F) GCCAGTCGACGAGGATGAGGAAGGG
Human IRF1 (R) CCAGCGGCCGCCTGCTACGGTGCAC
ChIP IRF1, -244 to -82 (F) GGGAGTGTGAGGGGTATCCT
ChIP IRF1, -244 to -82 (R) CATTCAACCAGCGGAAAACT
ChIP IRF1, -6842 to -6737 (F) GGCCTGCCCAAGAAAGAAACCAAA
ChIP IRF1, -6842 to -6737 (R) ACGTGCATGTGAGATATGCGAAGG
ChIP TaqMan, TNF promoter (F) GCGATGGAGAAGAAACCGAGACAGAA
ChIP TaqMan, TNF promoter (R) GGGTGTGCCAACAACTGCCTTTAT
ChIP TaqMan, TNF promoter (probe) /56-FAM/AGCTCATGG/ZEN/GTTTCTCCACCAAGGAA/3IABkFQ/
ChIP TaqMan, hHS-8 (F) GGCCTGCCCAAGAAAGAAACCAAA
ChIP TaqMan, hHS-8 (R) ACGTGCATGTGAGATATGCGAAGG
ChIP TaqMan, hHS-8 (probe) /56-FAM/AACCAAGAT/ZEN/TGGCCCATCTCAAGGAGCA/3IABkFQ/
ognizing exon 4 and exon 3 of the human TNF gene, the human GapdH gene, and the
human IRF1 gene (Table 2.4.1).
Measurement of TNF production
TNF secretion was quantified by ELISA specific for murine and human TNF (R&D) us-
ing a VMax®Kinetic ELISA Microplate Reader.
DNase I Hypersensitivity Assay (DHA)
DHAs were performed using both THP-1 cells and primary human MDMs. MDMs were
detached from culture surface using TrypLE™ (Life Technologies). Cells were harvested,
washed with PBS, and resuspended in RSB buffer (10mM Tris-HCl pH 7.4, 10mM NaCl,
and 3mM MgCl2). Cells were lysed with lysis buffer (0.5% NP-40 in 1x RSB buffer) on
ice for 5min. Resuspended nuclei in RSB buffer were treated with DNase I (40ng/ul) at
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37C for 5min. DNase I activity was quenched upon addition of stop solution (0.6M NaCl,
20mMTris-HCl pH 8.0, 10mMEDTA, and 1% SDS). Samples were treated with Proteinase
K at 56C O/N. DNA was digested with ScaI and BamHI restriction enzymes and analyzed
by Southern blotting using a radiolabeled P32 probe corresponding to the coding region of
LT-α. 10ug of DNA was used for each lane.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed with anti-IRF1 (H-205, Santa Cruz), Rb IgG (Diagenode),
anti-H3K27me3 (C36B11, Cell Signaling), anti-H3K27ac (ActiveMotif), and anti-H3 (Ab-
cam). THP-1 cells and primary humanMDMswere treated (IFN-γ 100ng/ml, LPS 100ng/ml),
fixed with 10% formaldehyde for 15min, treated with 2.5M glycine for 5min, harvested,
washed with PBS, lysed with 0.25% Triton X-100 and 0.5% NP-40 for 5min, centrifuged at
1200RPM for 10min, resuspended in 1% SDS lysis buffer, and sonicated 5min for 4 cycles
in a Biorupter. Sonicated DNA was set up for immunoprecipitation O/N and DNA-protein
complexes were recovered by adding Protein A/G Plus Agarose Beads (Thermo Scientific)
for 3h. Samples were washed 6 times with 1ml of wash buffer and treated with proteinase
K at 65C O/N. Samples were treated with phenol/chloroform before O/N ethanol precipi-
tation. DNA fragments for IRF1 recruitment were analyzed by quantitative real-time PCR
with Sybergreen master mix (Invitrogen) and primer sets for regions -244 to -82 (promoter)
relative to the TNF TSS and -6842 to -6737 (hHS-8) relative to the TNF TSS (Table 2.4.1).
Rb IgG percent input values were subtracted from IRF1 percent input values. DNA frag-
ments for H3K27me3 and H3K27ac analysis were analyzed by quantitative real-time PCR
using Jumpstart™ Taq ReadyMix™ For Quantitative PCR (Sigma) and primer/probe sets for
the TNF promoter and hHS-8 (Table 2.4.1). H3K27me3 and H3K27ac percent input values
were normalized to H3 percent input values.
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DNase I Footprinting Assay
Radiolabeled P32 fragments of the TNF promoter (-200 to +1) and hHS-8 (-7031 to -6782)
regions were incubated with recombinant IRF1 protein (Abcam) and treated with diluted
DNase I at RT for 5s before quenching enzyme activity with stop solution (0.13mM EDTA,
0.5% SDS, and tRNA). Samples were treated with phenol chloroform and DNA was pre-
cipitated O/N at -20C. G/A ladder was treated with 4% formic acid, radiolabeled with P32,
treated with 1M piperdine, and precipitated with n-butanol. DNA fragments were separated
by electrophoresis on an 8% sequencing gel.
Mice
6-8 week old C57BL/6J mice and B6.129S2-Irf1tm1Mak/J mice were purchased from Jack-
son Laboratories. Experimental procedures were done in accordance with the Institutional
Animal Care and Use Committee (IACUC) and the Harvard Medical Area Standing Com-
mittee on Animals (HMA IACUC).
Isolation, culture, and stimulation of murine BMDMs
For the generation of murine bone marrow-derived macrophages (BMDMs), bone mar-
row cells of wild type or Irf1-/- mice (6-8wks) were cultured in DMEM medium supple-
mented with 10% FBS, 10% L929 cell conditioned medium (LCCM), 100U/ml penicillin,
100ug/ml streptomycin, and 2mM L-glutamine. Cells were fed on day 5 and media was
changed on day 7, 3h before mIFN-γ (100ng/ml; R&D) and LPS (100ng/ml; Sigma E. coli
O111:B4) treatment. Supernatant was collected 2, 4, and 6h after treatment.
Short hairpin RNA
The lentiviral plasmid PLKO.1 expressing shRNA targeting human IRF1 was purchased
from the RNAi Consortium (TRC) Lentiviral shRNA library (Thermo Scientific). Clone
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TRCN0000014668 with a target sequence of CGTGTGGATCTTGCCACATTT was vali-
dated in our laboratory. Control shRNA encodes a scrambled sequence. Lentiviruses en-
coding shRNA sequences were generated by transfecting the packaging cell line HEK-293T
with the shRNA-encoding pLOK.1 plasmids in combination with the packaging plasmid
psPAX2 and the envelope plasmid pMD2.G using Effectene transfection reagent (Qiagen).
Supernatants were collected 48h post-transfection, clarified by centrifugation, and stored at
-80C. THP-1 cells were transduced with the lentiviral particles by culturing the cells with
supernatants from the virus-producing cells in the presence of 8ug/ml polybrene (Millipore)
and spinoculation for 2h at 2000RPM. Successfully transduced cells were selected and ex-
panded by treatment with 0.8ug/ml puromycin.
Electrophoretic Mobility Shift Assay (EMSA)
Radiolabeled P32 oligonucleotides were added to THP-1 nuclear extracts or recombinant
IRF1 protein (Abcam) in a binding buffer solution (10mM Tris-HCl pH 7.5, 53mM NaCl,
1mM DTT, 0.01% Nonidet-P40, 5% glycerol, and 0.05ug/ul of double-stranded poly(dI-
dC)) at RT for 30min. In super-shift experiments, samples were incubated with 2ug of
anti-IRF1 (H-205, Santa Cruz Biotechnology). Protein-DNA complexes were separated by
electrophoresis on a 5% PAAG gel.
Sequencing
Procurement of cell lines and samples of blood or DNA from representative individu-
als of the primate species and subspecies was previously described [197, 210]. Genomic
DNA was isolated using QIAamp DNA Blood kit (Qiagen). Sequence alignments were
performed using ClustalW2 multiple sequence alignment provided by EMBL-EBI.
Plasmids
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Construction of the TNF promoter-driven luciferase reporter was previously described
[189]. The TNF promoter with hHS-8 plasmid was constructed by inserting nucleotides
-7833 to -6583 relative to the TNF TSS into the TNF promoter-driven luciferase reporter
construct using MluI and NheI restriction enzyme sites. The TNF promoter with mutated
hHS-8 plasmid was constructed by circular site-directed mutagenesis.
Luciferase Reporter Assay
J774 cells were transfected with luciferase reporter constructs using an Effectene Trans-
fection Reagent kit (Qiagen). Cells were treated with mIFN-γ (100ng/ml; R&D) and LPS
(100ng/ml, Sigma E. coli O111:B4). Luciferase assays were performed 8h after treatment
under the Dual Luciferase Reporter Assay System (Promega) using a Dynex luminometer
and Renilla luciferase (pRL-TK) as a control.
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Chapter 3
Characterization of chromatin alterations at the TNF/LT locus
during endotoxin tolerance and its IFN-γ-mediated abrogation
3.1 Introduction
Sepsis is a major cause of death in modern intensive care units (ICUs) and accounts for a
huge financial burden on public health care systems [226]. It is caused by severe infection
and is classically characterized by an initial phase of uncontrolled systemic inflammation
that is uniquely followed by a prolonged immunosuppressive state [227–230]. Indeed, this
later, immunosuppressive phase frequently correlates with high risks of secondary infec-
tion and mortality during the patient’s ICU stay [231]. Studies have demonstrated that
blood monocytes isolated from sepsis patients who have entered the immunosuppressive
phase share several characteristics with endotoxin-tolerant monocytes and macrophages
[232–235]. Thus, an understanding of how monocytes and macrophages “switch” from in-
flammatory to immunosuppressive states could help clinicians more efficiently target the
later, more severe stages of sepsis.
As stated previously, endotoxin tolerance is the phenomenon in which immune cells, pri-
marily monocytes and macrophages, transiently become hyporesponsive or “tolerant” upon
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repeated or prolonged exposure of LPS [64]. In the case of sepsis, monocytes isolated from
sepsis patients and subsequently stimulated with LPS were shown to express significantly
lower levels of inflammatory cytokines like Il-1β, IL-6, and especially TNF, as compared
to LPS-induced monocytes from healthy individuals [232].
One study examining epigeneticmodifications at individual promoters inmurinemacrophages
demonstrated that chromatin modifications distinguish two distinct classes of genes during
endotoxin tolerance.“Class T” comprised genes that were tolerant upon repeated challenges
of LPSwhile “class NT” comprised genes that remained inducible upon repeated challenges
of LPS [236]. Importantly, “class T” promoters in contrast to “class NT” promoters re-
mained primarily deacetylated and failed to recruit the chromatin remodeling protein Brg1.
This and the work of others demonstrate the importance of examining chromatin modifi-
cations at individual promoters when determining mechanisms for selective modulation of
inflammatory responses [237, 238].
Notably, IFN-γ priming has been shown to abrogate endotoxin tolerance, thereby restor-
ing responses to LPS stimulation in monocytes and macrophages [73]. Using primary hu-
man monocytes, IFN-γ priming was shown to restore IL6 transcription by promoting chro-
matin accessibility at the human IL6 promoter [239]. Thus, the mechanisms responsible for
the induction and abrogation of endotoxin tolerance involve chromatin remodeling. Few
studies have focused on TNF gene regulation in the context of endotoxin tolerance [239–
241] and none to our knowledge have looked beyond the promoter. Here, by examining the
TNF/LT locus, we argue that alterations in chromatin modifications at the TNF promoter
and distal DNA elements play a major role in the induction and IFN-γ-mediated abrogation
of endotoxin tolerance. Specifically, we have shown that H3K27me3 marks the minimal
TNF promoter in endotoxin-tolerant macrophages. In addition, we look beyond the TNF
promoter and observe the appearance of an IFN-γ-inducible DH site that is 4kb upstream
of the TNF TSS.
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3.2 Results
3.2.1 IFN-γ restoresTNF gene expression in endotoxin-tolerantmonocytes andmacrophages.
To induce endotoxin tolerance, we treated primary human MDMs with LPS (100ng/ml)
for 24h followed by a second challenge of LPS (100ng/ml) (Figure A.1.1). From past in
vitro studies, methods for inducing endotoxin tolerance vary with regards to the number of
LPS challenges and the concentration of LPS used for each challenge. Despite these varia-
tions in experimental design, it is generally accepted that repeated or prolonged exposure of
LPS induces endotoxin tolerance in monocytes and macrophages. We next measured TNF
mRNA levels from both endotoxin-tolerant (T) and non-tolerant (LPS) MDMs stimulated
with LPS. We observed a significant decrease in mRNA levels from endotoxin-tolerant
MDMs as compared to non-tolerant MDMs, which suggests that the mechanism(s) of en-
dotoxin tolerance targets TNF transcription (Figure 3.2.1a). We also observed the effects of
IFN-γ priming by pretreating endotoxin-tolerant MDMs with IFN-γ 2h before the second
challenge of LPS (Figure A.1.1). As reported in primary human monocytes [239], IFN-γ
priming partially restores the TNF response in endotoxin-tolerant MDMs (Figure 3.2.1a).
We also confirmed the induction and abrogation of endotoxin tolerance in THP-1 cells, a
human monocytic cell line, using the same experimental design (Figure 3.2.1b).
3.2.2 IFN-γ abrogates endotoxin tolerance in an IRF1-independent manner.
Considering the mechanism that we have defined for IFN-γ priming in non-tolerant THP-1
cells and primary human MDMs, we sought to understand whether IRF1 plays a major role
in the ability of IFN-γ to restore TNF gene expression in endotoxin-tolerant cells. THP-1
cells were transfected with either shRNA targeting human IRF1 or control shRNA encod-
ing a scrambled sequence. Sufficient knockdown of IRF1 mRNA was observed when cells
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Figure 3.2.1: IFN-γ restores TNF gene expression in endotoxin-tolerant monocytes and macrophages. (a) Primary
human MDMs were stimulated (experimental design Figure A.1.1), and TNF mRNA levels were measured. Data
from 3 separate donors. (b) THP-1 cells were stimulated as in (a) and TNF protein levels in supernatants were
measured by ELISA post LPS stimulation (shown relative to LPS values). (*) p  0:05 and (***) p  0:001.
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Figure 3.2.2: IFN-γ abrogates endotoxin tolerance in an IRF1-independent manner. THP-1 cells expressing IRF1
and control shRNA were stimulated, and TNF mRNA levels were measured (shown relative to LPS values). (*)
p  0:05, (**) p  0:01, and (***) p  0:001.
were treated with IFN-γ for 3h (Figure 2.2.4b), which we concluded as sufficient knock-
down of IRF1 protein considering its extreme instability (half-life 30min) [215]. As ex-
pected, IFN-γ priming partially restored TNF gene expression in endotoxin-tolerant THP-
1 cells expressing control shRNA (Figure 3.2.2). Importantly, partial restoration of TNF
gene expression also occurred in endotoxin-tolerant THP-1 cells expressing IRF1 shRNA,
demonstrating that IFN-γ does not require IRF1 to restore the TNF response during endo-
toxin tolerance. We hypothesize that two distinct mechanisms are responsible for the effects
of IFN-γ in LPS responsive and non-responsive monocytes and macrophages.
3.2.3 IFN-γ promotes chromatin accessibility at the TNF promoter in endotoxin-tolerant
monocytes.
We next examined changes in chromatin accessibility at the TNF/LT locus during the induc-
tion and abrogation of endotoxin tolerance by performing DNase I hypersensitivity assays
(DHAs). We hypothesized that the induction of endotoxin tolerance results in decreased
chromatin accessibility at the TNF promoter, and that IFN-γ-mediated abrogation of endo-
toxin tolerance results in the restoration of accessibility. DNA from endotoxin-tolerant and
61
non-tolerant THP-1 cells stimulated with IFN-γ was partially digested with DNase I. KpnI
digestion allowed for visualization of DNase I hypersensitivity at the TNF promoter (Figure
3.2.3a). When comparing endotoxin-tolerant and non-tolerant monocytes stimulated with
LPS, we observed minimal differences in DNase I hypersensitivity at the TNF promoter
(Figure 3.2.3b, lane 6 compared to lane 8). We conclude that inhibition of TNF mRNA
levels during endotoxin tolerance is not a result of decreased chromatin accessibility at the
TNF promoter.
In fact, we observed increased chromatin accessibility, as evidenced by a slight widening
of the band representing the TNF promoter (Figure 3.2.3b, lane 10). This suggests the
appearance of an additional DH site, which may play a role in the mechanism by which
IFN-γ priming restores TNF gene expression in endotoxin tolerance.
3.2.4 H3K27me3 and H3K27ac levels at the TNF promoter predict both the induction and
abrogation of endotoxin tolerance in human monocytes and macrophages.
We next investigated histone modifications at the TNF promoter during the induction and
abrogation of endotoxin tolerance, and identified two modifications that mark LPS respon-
sive and non-responsive monocytes and macrophages. ChIP studies showed significant
enrichment of H3K27me3 levels at the TNF promoter in endotoxin-tolerant THP-1 cells
(Figure 3.2.4a). Conversely, endotoxin-tolerant cells primed by IFN-γ showed no enrich-
ment for H3K27me3 levels at the TNF promoter. Results were repeated in primary human
MDMs isolated from a representative donor (Figure 3.2.4b). We also observed a com-
plementary response in H3K27ac levels at the TNF promoter in response to the induction
and the abrogation of endotoxin tolerance. Specifically, IFN-γ priming resulted in a dra-
matic increase of H3K27ac levels at the TNF promoter in endotoxin-tolerant monocytes
and macrophages (Figure 3.2.4c, 3.2.4d), which supports the previous finding of increased
chromatin accessibility at the TNF promoter (Figure 3.2.3b). This data identifies distinct
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Figure 3.2.3: IFN-γ promotes chromatin accessibility at the TNF promoter in endotoxin-tolerant monocytes. (a)
Map of the human TNF/LT locus. DH sites and positions and directions of transcription of the TNF, LTA, and LTB
genes are shown. Positions of the parental KpnI and DNase I digestion products for the DHA are indicated. Frag-
ment representing DNase I accessibility at the TNF promoter is 6.5kb in length. (b) IFN-γ increases DNase I cleav-
age at the TNF promoter in endotoxin-tolerant THP-1 cells.
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histone modifications at the TNF promoter that associate with the induction and abrogation
of endotoxin tolerance.
3.2.5 IFN-γ induces the formation of hHS-4 at the TNF/LT locus in endotoxin-tolerant
human monocytes.
In addition to the TNF promoter, we observed chromatin alterations at distal DNA elements
within the TNF/LT locus during the induction and abrogation of endotoxin tolerance. DNA
from endotoxin-tolerant and non-tolerant THP-1 cells stimulated with and without IFN-γ
was partially digested with DNase I. ScaI digestion allowed for visualization of both hHS-8
and hHS-4 (Figure 3.2.5a). We detected a strongly enhanced band corresponding to hHS-8
from endotoxin-tolerant cells as compared to non-tolerant cells stimulated with LPS (Figure
3.2.5b, lane 9 compared to lane 12). In addition, increased chromatin accessibility at hHS-8
was sustained in endotoxin-tolerant cells treated with IFN-γ. Past studies have shown that
CBP/p300 is recruited to the TNF promoter in monocytes and macrophages activated by
LPS [189]. We speculate that prolonged exposure and additional challenges of LPS induce
continued CBP/p300 recruitment to the TNF promoter, thereby promotingDNase I cleavage
at hHS-8.
Furthermore, IFN-γ priming in endotoxin-tolerant cells resulted in the formation of the
DH site hHS-4 (Figure 3.2.5b, lane 15). This DH site is located 4kb upstream of the TNF
TSS and lies within the LTA promoter. Although hHS-4 (Figure A.1.2) is not constitutively
present in monocytes and macrophages, studies from the Goldfeld lab have shown that
hHS-4 is constitutively present in CD4+ T cells (unpublished data). We also observed a
slight increase in DNase I cleavage at hHS-4 in non-tolerant monocytes primed by IFN-γ.
It is important to note that although non-tolerant and endotoxin-tolerant cells are primed by
IFN-γ for the same duration (2h), induction of hHS-4 is significantly stronger in endotoxin-
tolerant cells. This suggests that endotoxin tolerance provides an environment that promotes
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Figure 3.2.4: H3K27me3 and H3K27ac levels at the TNF promoter predict both the induction and abrogation of
endotoxin tolerance in human monocytes and macrophages. (a) Induction of endotoxin tolerance correlates with
an enrichment of H3K27me3 at the TNF promoter. ChIP using THP-1 cells and analyzing H3K27me3 prevalence.
(b) ChIP as in (a) using primary human MDMs from a representative donor. (c) Abrogation of endotoxin tolerance
correlates with an enrichment of H3K27ac at the TNF promoter. ChIP using THP-1 cells and analyzing H3K27ac
prevalence. (d) ChIP as in (c) using primary human MDMs from a representative donor. (*) p  0:05, (**) p 
0:01, and (***) p  0:001.
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chromatin accessibility at hHS-4.
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Figure 3.2.5: IFN-γ induces the formation of hHS-4 at the TNF/LT locus in endotoxin-tolerant human monocytes.
(a) Map of the human TNF/LT locus. DH sites and positions and directions of transcription of the TNF, LTA, and
LTB genes are shown. Positions of the parental ScaI and DNase I digestion products for the DHA are indicated.
Fragment representing DNase I accessibility at the hHS-8 and hHS-4 is 5kb and 1.4kb in length, respectively. (b)
IFN-γ dramatically increases DNase I cleavage at hHS-4 in endotoxin-tolerant THP-1 cells, as compared to non-
tolerant THP-1 cells.
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3.3 Discussion
Recent studies have highlighted the importance of examining chromatin and its environment
when describing endotoxin tolerance and its IFN-γ-mediated abrogation. In this study, we
have characterized the TNF/LT locus in endotoxin-tolerant monocytes and macrophages
and found the TNF promoter to be nuclease accessible and enriched for H3K27me3 lev-
els during repressed transcription. We have also found that IFN-γ priming restored TNF
gene expression in an IRF1-indepenent manner; furthermore, we observed an enrichment
of H3K27ac levels at the TNF promoter and the appearance of a DH site 4kb upstream
of the TNF TSS. These results support the finding that chromatin modifications at both the
TNF promoter and distal DNA elements are critical for determining mechanisms for the
induction of endotoxin tolerance and its IFN-γ-mediated abrogation.
We speculate that TNF and IL6 genes are silenced by different mechanisms, and that
mechanisms responsible for transcriptional silencing during endotoxin tolerance vary be-
tween genes and their respective loci. One study showed that LPS stimulation in endotoxin-
tolerant murine macrophages resulted in decreased nuclease accessibility at the IL6 pro-
moter, providing evidence for a nucleosome barrier that blocks LPS-induced IL6 gene ex-
pression [236]. Importantly, the authors noted that they did not detect enrichment of the
normally repressive histone modification H3K27me3 at the IL6 promoter. Another study
confirmed these results and also demonstrated that priming human monocytes with IFN-
γ prevents endotoxin tolerance, evidenced by restored IL-6 mRNA levels and chromatin
accessibility at the IL6 promoter [239]. In contrast, we observed comparable levels of nu-
clease accessibility at the TNF promoter in non-tolerant and endotoxin-tolerant monocytes
stimulated with LPS. In addition, we observed an increase in H3K27me3 levels at the TNF
promoter. Our data suggest that, unlike IL-6, TNF gene repression in endotoxin-tolerant
monocytes does not involve alterations in chromatin accessibility at the promoter.
68
What then is the mechanism of TNF gene repression during endotoxin tolerance? As
stated previously, H3K27me3 has been shown to increase the affinity of the chromodomain
of the Drosophila Polycomb protein for histone tails, and this has been implicated in the
maintenance of gene silencing [138, 139]. However, mechanisms of Polycomb mediated
repression remain unknown. Notably, one study examining the TNF promoter in endotoxin-
tolerant THP-1 cells observed an enrichment of H3K9me2 levels and an increase in DNA
methylation, as compared to non-tolerant THP-1 cells stimulated with LPS [240]. They also
show recruitment of both the H3K9 histone methyltransferase G9a and the DNA methyl-
transferase Dnmt3a/b to the TNF promoter during endotoxin tolerance. Unfortunately, we
were unable to repeat the H3K9me2 findings. Future experiments will have to explore the
functional role of histone and DNA methylation in TNF gene repression during endotoxin
tolerance.
We found chromatin modifications during IFN-γ-mediated abrogation of TNF gene re-
pression to be similar to that of IL6; specifically, we observed an increase in nuclease acces-
sibility and an enrichment of H3K27ac levels at the TNF promoter. Notably, past studies
have prevented induction of endotoxin tolerance by pretreating cells with IFN-γ before the
initial LPS challenge [239] whereas our work investigates the ability of IFN-γ to abrogate
endotoxin tolerance after it has been induced. We find our work to be clinically more rele-
vant when thinking of potential therapeutic targets for sepsis patients whose monocytes and
macrophages have already entered an immunosuppressed state.
In addition, we have shown that IRF1 does not play a critical role in the ability of IFN-
γ to restore TNF gene expression in endotoxin-tolerant cells, which suggests that IFN-γ
priming employs distinct mechanisms for enhancing TNF transcription in resting cells as
compared to endotoxin-tolerant cells. This we found unsurprising considering the fact that
the chromatin environment of the TNF/LT locus is markedly different between resting and
endotoxin-tolerant cells; thus, IFN-γ stimulation must employ distinct mechanisms to pro-
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mote a chromatin environment that favors enhanced TNF gene expression. It will be impor-
tant to identify transcription factors and chromatin remodeling enzymes essential for IFN-γ-
mediated abrogation of endotoxin tolerance; STAT1may play an important role considering
its activation by IFN-γ signaling.
Finally, identification of hHS-4 as an IFN-γ-inducibleDH site in endotoxin-tolerantmono-
cytes suggests its role as a distal regulatory element. Although hHS-4 lies within or near the
LTA promoter [242], preliminary experiments have shown that IFN-γ does not induce LT-α
expression in endotoxin-tolerant monocytes or macrophages (data not shown). Notably,
hHS-4 is constitutively present in CD4+ T cells; thus, it may function as both a promoter in
lymphocytes and an IFN-γ-inducible regulatory element in endotoxin-tolerant monocytes
and macrophages. Future experiments will have to explore the functional role of hHS-4,
particularly as an enhancer or insulator.
3.4 Materials and Methods
Cell culture and stimulations
THP-1 cells were maintained in RPMI-1640 supplemented with 10% FBS. For primary
human MDMs, enriched populations of human monocytes were isolated from healthy hu-
man donor buffy coats using a CD14+ positive selection kit (Stemcell). MDMs were ob-
tained after 6d of culture in RPMI-1640 medium supplemented with 5% human serum AB
(Gemcell) and GM-CSF (50ng/ml; Peprotech). Cells were treated with IFN-γ (100ng/ml;
R&D) and LPS (100ng/ml; Sigma E. coli O111:B4).
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted from cells with a QuickRNAMini kit (Zymo) and treated with
Turbo DNA-free kit (Invitrogen). cDNAwas synthesized from total RNA with M-MLV re-
verse transcriptase (Invitrogen) and 20-residue oligo (dT) (Invitrogen). TNF mRNA levels
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were measured by the change-in-threshold (ΔΔCt) method based on quantitative real-time
PCR in an iCycler iQ (Bio-rad) with SyberGreen Master Mix (Invitrogen) and primers rec-
ognizing exon 4 and exon 3 of the human TNF gene and the human GapdH gene (Table
2.4.1).
DNase I Hypersensitivity Assay (DHA)
DHAs were performed using THP-1 cells. Cells were harvested, washed with PBS, and
resuspended in RSB buffer (10mMTris-HCl pH 7.4, 10mMNaCl, and 3mMMgCl2). Cells
were lysed with lysis buffer (0.5% NP-40 in 1x RSB buffer) on ice for 5min. Resuspended
nuclei in RSB buffer were treated with DNase I (40ng/ul) at 37C for 5min. DNase I activity
was quenched upon addition of stop solution (0.6M NaCl, 20mM Tris-HCl pH 8.0, 10mM
EDTA, and 1% SDS). Samples were treated with Proteinase K at 56C O/N. For analysis of
hHS-4, DNAwas digested with either ScaI or KpnI and analyzed by Southern blotting using
a radiolabeled P32 probe corresponding to the coding region of LTA or hHS-8, respectively.
10ug of DNA was used for each lane.
Chromatin immunoprecipitation (ChIP)
ChIP assayswere performedwith anti-H3K27me3 (C36B11, Cell Signaling), anti-H3K27ac
(Active Motif), and anti-H3 (Abcam). THP-1 cells and primary humanMDMs were treated
(IFN-γ 100ng/ml, LPS 100ng/ml), fixed with 10% formaldehyde for 15min, treated with
2.5M glycine for 5min, harvested, washed with PBS, lysed with 0.25% Triton X-100 and
0.5% NP-40 for 5min, centrifuged at 1200RPM for 10min, resuspended in 1% SDS ly-
sis buffer, and sonicated 5min for 4 cycles in a Biorupter. Sonicated DNA was set up
for immunoprecipitation O/N and DNA-protein complexes were recovered by adding Pro-
tein A/G Plus Agarose Beads (Thermo Scientific) for 3h. Samples were washed 6 times
with 1ml of wash buffer and treated with proteinase K at 65C O/N. Samples were treated
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with phenol/chloroform before O/N ethanol precipitation. DNA fragments for H3K27me3
and H3K27ac analysis were analyzed by quantitative real-time PCR using Jumpstart™ Taq
ReadyMix™ For Quantitative PCR (Sigma) and a primer/probe set for the TNF promoter
(Table 2.4.1). H3K27me3 and H3K27ac percent input values were normalized to H3 per-
cent input values.
Short hairpin RNA
The lentiviral plasmid PLKO.1 expressing shRNA targeting human IRF1 was purchased
from the RNAi Consortium (TRC) Lentiviral shRNA library (Thermo Scientific). Clone
TRCN0000014668 with a target sequence of CGTGTGGATCTTGCCACATTT was vali-
dated in our laboratory. Control shRNA encodes a scrambled sequence. Lentiviruses en-
coding shRNA sequences were generated by transfecting the packaging cell line HEK-293T
with the shRNA-encoding pLOK.1 plasmids in combination with the packaging plasmid
psPAX2 and the envelope plasmid pMD2.G using Effectene transfection reagent (Qiagen).
Supernatants were collected 48h post-transfection, clarified by centrifugation, and stored at
-80C. THP-1 cells were transduced with the lentiviral particles by culturing the cells with
supernatants from the virus-producing cells in the presence of 8ug/ml polybrene (Milli-
pore) and spinoculation for 2h at 2000RPM. Successfully transduced cells were selected
and expanded by treatment with 0.8ug/ml puromycin.
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Chapter 4
Concluding Remarks
The overarching goal of this thesis project was to use the TNF/LT locus as a model system to
identify and dissect mechanisms of chromatin remodeling that control classical macrophage
activation and endotoxin tolerance. In doing so, we have provided a mechanistic explana-
tion of how IFN-γ poises the TNF/LT locus for enhanced TNF transcription upon LPS stim-
ulation, while at the same time providing potential targets for selective manipulation of TNF
expression in primed macrophages. We have also characterized the chromatin environment
at the TNF/LT locus during the induction and IFN-γ-mediated abrogation of endotoxin tol-
erance. More generally, we have examined long-range distal DNA elements of the TNF/LT
locus and demonstrated the importance of examining DNA elements beyond the promoter
when investigating the elaborate nature of inflammatory responses and developing novel
therapeutics for inflammatory diseases.
Importantly, distal DNA elements, particularly enhancers, are thought to be of primary
importance when determining cell type-specific gene expression [122]. This is supported
by the finding that enhancers have been observed to be largely cell selective, to be marked
with cell type-specific histone modification patterns, and to actively function in a cell type-
specific manner. Promoters, in contrast, have been observed to appear and function in a
similar manner across cell types. In the TNF/LT locus, hHS-8 is present in the primary
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producers of TNF (i.e., monocytes, macrophages, and T cells); it is of interest to examine
whether hHS-8 is present in other cells that are not primary producers of TNF.
As stated previously, studies using mice with cell type-specific deletions of the TNF
gene have suggested that novel therapies for autoimmune diseases that specifically target
myeloid-derived TNF would be preferable in latently infected TB patients [39]. In the case
of our proposed model for IFN-γ priming, hHS-8 and its chromatin environment may pro-
vide potential targets for selectivemanipulation of TNF expression inmonocytes/macrophages
as compared to T cells. Although HSS-9 (murine hHS-8) was shown to function as an in-
ducible enhancer inmurine T cells [177], we hypothesize that transcription factors, chromatin-
remodeling enzymes, and patterns of histone modifications will differ at hHS-8 between T
cells andmonocytes/macrophages. This is similarly seen at the TNF promoter when looking
at enhanceosome formation in T cells and monocytes/macrophages [175].
In addition to demonstrating a high degree of cell type-specificity, distal DNA elements
can be inducible and inducer-specific. Thus, it is critical to search for distal DNA elements
in model systems that represent disease states. For example, in the TNF/LT locus, hHS-
4 has been shown to be cell type-specific between resting primary monocytes and CD4+
T cells, and we have now shown hHS-4 to be inducer-specific within endotoxin-tolerant
monocytes and macrophages. This finding demonstrates that selective modulation of indi-
vidual genes of the inflammatory response requires a thorough understanding of inducible
chromatin modifications for both the promoter and distal regulatory elements in different
settings of pathology. In the case of TNF dysregulation, future experiments would ideally
examine chromatin modifications at the TNF/LT locus in resting and IFN-γ-treated mono-
cytes isolated from sepsis patients.
Lastly, we have identified hHS-8 and hHS-4 by DNase I hypersensitivity assays (DHAs)
followed by Southern blotting. This method is feasible for identifying distal DNA elements
50kb from the target promoter; however, regulatory elements have been described as tens
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to hundreds of kilobases away from their target promoter. Indeed, identifying distal DNA
elements with respect to target genes can be quite challenging. Often times, distal DNA
elements are assigned the closest gene as their target gene; unfortunately, there has been
no report to date on the rate of false positives for this strategy. A recent study has applied
chromosome conformation capture (3C) assay technology to identify interactions between
transcription start sites (TSSs) and previously identified distal DNA elements throughout
the human genome [174]. Considering the fact that enhancers are often found to be in close
proximity with their target promoters, this method is thought to hold promise in identifying
a percentage of target promoters. Ultimately, a greater understanding of how enhancers and
other types of regulatory elements mechanistically function is required for high throughput
methods of classifying regulatory elements with their target promoters.
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Appendix A
Supplemental Figures
A.1 Supplemental Figures
76
(a)
(b)
Figure A.0.1: IFN-γ promotes chromatin accessibility at hHS-8 in the TNF/LT locus. IFN-γ does not affect DNase
I cleavage at the TNF promoter. DHA using THP-1 cells. DNase I digestion products for the DHAs are indicated;
fragment representing DNase I accessibility at the TNF promoter and hHS-8 is 3kb and 5kb in length, respec-
tively. (c) IFN-γ strongly increases DNase I cleavage at hHS-8.
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Figure A.0.2: THP-1 cells were stimulated, and IRF1 mRNA levels were measured.
Human
Mouse
-6838 -6785
TGCCCAAGAAAGAAACCAAATT-CATACAACCTCCGAAACTGAGATTGAAACCAA
TGCCCAAGAGGGAAACTGAATTTCACACAACCTCTAAAACTGAGATTGAAACCAA
Free probe
– rIR
F1
– rIR
F1
Human Mouse
1 2 3 4
Figure A.0.3: rIRF1 binds to hHS-8 in both the human and mouse TNF/LT locus. EMSA was performed with rIRF1
and human and mouse radiolabeled P32 oligonucleotides of sequences for positions -6838 to -6785.
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GCTGGATGAAATCTAGAGGCTTTAC-CCTTCTTGCATGGCCCTGCATGACCTGGCCCCTGCCCTCCTCTCTGACCTCATC 
GTTGAATAAAATGGAGATACTTTGTGTCTTC----------TCACATGGTCTGGC-CCTGCCTTCCTCTCCCACTGCATC                   
* ** ** ****  ***  ****    ****             ****  ***** ****** *******  **  ****  
TCCCACCCGCCTCCCAGTCTCTCTC-TCTGCTCCAGCCACACTGGCCTTCTGTTTGTCGTCAACACCCCCAGCTTGGTTC  
TG--ACC--TCTTCAAGTGTCTCTGATGTGGTCAAGT-TCAGTTTCTTGCTGT---CCATCAGCATCCCTGGCTTCCTCC                  
*   ***   ** * *** *****  * ** ** **   ** *  * * ****    * *** ** ***  ****  * *  
CGCCTTCCAGCCTTTGCAGTAGCTGCTCCCTTTACCTGAAATGCT----TTGCTCCCAAACTTTTACCTGGTCACTATTT 
CTCCTCCCTACCTATCTGTCACCTGGGCCTTTT-CTT-CAGTGCTACCCTTGCTGAGAGTCACATTACTGAGTGCTGTAT                  
* *** **  *** *     * ***  ** *** * *  * ****    *****   *  *   *  ***    ** * *  
TTT-GTCATTTGGGTCTCAG------CTCCA--GTGCCACCCAAACACTCAAAGAGGATTTTGCTGACT-ACTGTATTTA 
CCAAGAGTATTCTCTTCCACTCCCCACGCCACCCTGCCTTGTTATCCCTGTAGGACTGTTTTACAGATTCATTTTATTTT 
    *    **   *  **       * ***   ****     * * **  * **   **** * ** * * * *****   
AAAG-----------TAGCTCCCTGCCACTCTTACAACATCAGCCTGTCTTATTTTCTCATAGTACCAATTTCTTCTTCA 
ATGGCGATGCTGGGGATGGTCCCTGGGTCTCACTCACGCTAGGCAAGTGCTC-TATCTCTAA-GACACATCCCTGCTCTT 
*  *             * ******   ***   **   *  **  **  *  * ****  *  **  **  ** **     
GTTTCTTTCTTTTCCGTCTGGCCTCACTGGAATACAAGCTCCACAGGTGCTGGTACCTTCTC--TGATCCCTTTGCCTCC 
TGATGTGTCTTTTCCATCTGGCCTGGCTGGAACATGATCCCTAAGAGTAAAGG-ATTTACTCTTAGGATTCTTTGGCTCA 
   * * ******** ********  ****** *  * * * *   **   ** *  * ***   *    ***** ***   
ATGTCCCTCCTGCCTTAGGACAATGCCCAGCATGTGTTAGGCACGCAGATACTCACTAAATGGAGGAATGGATGAATAAT 
A----CTTTGTGCCACAGTATACTTCCTGCCTTG-----------AACAAACTTCCTGGTTGGT--ACTCAGTAAAC--- 
*    * *  ****  ** * * * **   * **            * * ***  **   ***   * *   * **      
TCATAAAGCAGGATAAAGTTCAACTTTAGGCTTGTGGCTCAGATTGGACTTACATTTAGAGTCAGATTTAAGTTTAGTGT 
--------ATGTATTAAAAGCTGTTGGAGG-GTGCGG-TGAGGTAGGACA---AT----GTCCAGCTCTAATTTCTGGCT 
          * ** **   *   *  ***  ** ** * ** * ****    **       *** * *** **  *  *  
TAGGAGTGGTGGTAAACTGGTTTCAAGATTAGCCCTAGAAACAGGGTTGGGTTGGGGTAGAGGAGAAGTTTTATTTAGGG 
CAG--------GTA---------GAAGTTCAACACCAGAGACAGGGTAA-GCTGTTTCACAGGAAGGAGTTTATTTGAGA 
 **        ***          *** * * * * *** *******   * **    * ****     *******  *   
GGTTATTAATTGGGATGTGTTTAGATTTAAGGTTAGGGTTACAGTTGGGGTTGAGTTTGAGTTGTGATTTGGGTTGAGGT 
GTCCTTTGAGGGGTATGTGCTTAGATTTGAGGTT------AC------------GTTTGAATTGTGATTTGGGTGAAGGT 
*    ** *  ** ***** ******** *****      **            ****** *************  ****  
TAAATTTGGGTTAGGGTTGATGTTGGTATTAAATCCCAATTCAGGTTTTGAGGCTAAGTTCAAGTTTGAAGCTAATGTCA 
TAAACTTGGGTAAAATCTGAGGCTA---AAAAA-------ACAGAGACTCACAGT-AG----TCTTTG--ACTACTGTCA 
**** ****** *    *** * *      ***        ***    * *   * **      ****   *** *****  
TTTCAGTCTCATTTGGAGGCTTCAGAGATTTCACTAGTTTCTCCACAAAGACCACTATAAAGACTGTATTTCCCTGAGTC 
GTTCAGCCTGGTTTGCAGGCTCCGGAGCTTTCTGTGGCCCTTCCTGAGAGT-GGTT--ATAGAC---------------- 
 ***** **  **** ***** * *** ****  * *    ***  * **     *  * ****                  
TGGGGCACAAGACTCC-AGTCATCAGCTCTCCCACCCAGGGAAAGTCCCAAACCAACTGCTGGCCTGCCCAAGAAAGAAA
-GATGCACAAGACTCCTAGTCATCAGCCCTCCCCCCCGGGGAAAGTCCCAGA-CAGCTGTTGGCCTCCCCAAGAGAGAAA 
 *  ************ ********** ***** *** ************ * ** *** ****** ******* *****  
CCAAA-TTCATACAACCTCCGAAACTGAGATTGAAACCAAGATTGGCCCATCTCAAGGAGCATCCTTC-GCATATCTCAC 
CTGAATTTCACACAACCTCTAAAACTGAGATTGAAACCAAAATTGGCCCATGGCAAGGCATATCCGCCAGCGTGCTGCCA               
*  ** **** ********  ******************* **********  *****   ****  * ** *    *    
ATGCACGTGACACTGAGCCTCAGCCCAGTCTTACCCTTCCTTCCTCTGTGTCTCTCATGTCT-----CCCCATCACCCTT 
GCTCCCGTGACACA--G-CTTAGCCAAGGCTTACCCTTCCTTCGTCTGTCTCCATCATCCCCTTATGCACCCTCTCCTTT                   
   * ********   * ** **** ** ************** ***** **  ****  *      * ** ** ** **  
CT--TGCCT-------TCCCT---TTTTTGTCT--TTCAATGTCCCATTCTTCCTCTTT---AATTTAAATTTCTCTCTG 
CCTCTGCCCCTCCAGGTCCCAGCCTTCTGCTCTGACTCAA-ATCTAATCCTCTCTCTGTCTCTCTTTCTGTCTCTCTCTG                  
*   ****        ****    ** *  ***   ****  **  ** **  **** *     ***   * ********  
T------------GTCTCACTGTTA--ATTGCAA-TACC 
TCTCTGTCTCTGTCTTTCTCTGTCTCCGTCTCTCTGTCT              
*             * ** ****     *  *     *    
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
Human
Mouse
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1250
1180
Figure A.0.4: hHS-8 is highly conserved between human and mouse. Alignment of human and mouse sequences
of hHS-8 (1250bp).
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21
Free probe
WT Mu
TGCCCAAGAAAGAAACCAAATTCATACAACCTCCGAAACTGAGATTGAAACCAA
TGCCCAAGAGGGAGGCCAAATTCATACAACCTCCGAGGCTGAGATTGAGGCCAA
WT
Mu
-6785-6838
Figure A.0.5: Nucleotide changes in the critical -GAAA- motifs disrupt rIRF1 binding. EMSA was performed with
rIRF1 and wildtype (wt) and mutant (mu) radiolabeled P32 oligonucleotides (sequences for positions -6838 to -
6785).
-
LPS
Figure A.0.6: p300 is recruited to hHS-8 upon LPS stimulation. ChIP using primary human MDMs and analyzing
p300 recruitment to hHS-8. Stimulations were IFN-γ alone for 3h, LPS alone for 1h, and both IFN-γ and LPS (IFN-γ
pretreatment for 2h followed by LPS treatment for 1h). (*) p  0:05. Data from 3 separate donors.
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Figure A.1.1: Experimental design of endotoxin tolerance induction and IFN-γ-mediated abrogation of endotoxin
tolerance.
CCTCACCCATGTGGAATTCTG--------AAACTTCCTTTGTAGAAAACTTTGGAAGGTG 52
-ATAAATGATGAGCAAATTTATATACAACAAAGTTATCTGTCATAAATATATGTAAGAAG 59
  * *   *** * ** * *         *** **   *   * ***  * ** ***  *
TCTGCCACATTGATCCTGGAATGTGTGTTTATTTGGGGTTATATAAATCTGTTCTGTG-- 110
TA------ATAAGTCCTTTG-TGTGTGTTTATGTGTGGTTATATGTATGTGTGCTGTGTG 112
*       **   ****    *********** ** ********  ** *** *****  
--GAAGCCACCTGAAGTCA--- 127
TGGAAGCCA---GAGGACAACC 131
  *******   ** * **   
Human
Mouse
Human
Mouse
Human
Mouse
Figure A.1.2: hHS-4 is highly conserved between human and mouse. Alignment of human and mouse sequences
of hHS-4 (120bp).
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